An empirical and theoretical investigation of psychodynamic psychotherapy and neuroleptic medication for the treatment of schizophrenia by Peters, Eric J.
University of Tennessee, Knoxville 
TRACE: Tennessee Research and Creative 
Exchange 
Doctoral Dissertations Graduate School 
5-2009 
An empirical and theoretical investigation of psychodynamic 
psychotherapy and neuroleptic medication for the treatment of 
schizophrenia 
Eric J. Peters 
University of Tennessee 
Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss 
Recommended Citation 
Peters, Eric J., "An empirical and theoretical investigation of psychodynamic psychotherapy and 
neuroleptic medication for the treatment of schizophrenia. " PhD diss., University of Tennessee, 2009. 
https://trace.tennessee.edu/utk_graddiss/6049 
This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee 
Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized 
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact 
trace@utk.edu. 
To the Graduate Council: 
I am submitting herewith a dissertation written by Eric J. Peters entitled "An empirical and 
theoretical investigation of psychodynamic psychotherapy and neuroleptic medication for the 
treatment of schizophrenia." I have examined the final electronic copy of this dissertation for 
form and content and recommend that it be accepted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy, with a major in Psychology. 
Leonard Handler, Major Professor 
We have read this dissertation and recommend its acceptance: 
Accepted for the Council: 
Carolyn R. Hodges 
Vice Provost and Dean of the Graduate School 
(Original signatures are on file with official student records.) 
To the Graduate Council:  
 
I am submitting herewith a dissertation written by Eric J. Peters entitled, “An Empirical 
and Theoretical Investigation of Psychodynamic Psychotherapy and Neuroleptic 
Medication for the Treatment of Schizophrenia.” I have examined the final paper copy of 
this dissertation for form and content and recommend that it be accepted in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in 
Psychology. 
            
____________________________ 
Leonard Handler, Major Professor 
 
We have read this dissertation 
and recommend its acceptance 
 
Robert G. Wahler_________ 
 




 Accepted for the Council: 
 
   Carolyn R. Hodges_____ 
 
   Vice Provost and Dean of the  










An empirical and theoretical investigation of psychodynamic psychotherapy and 














A Dissertation Project  
Presented for the 
Doctor of Philosophy  
Degree 




































for being you 
 
 
To Bev, because you know in your experience and very being: 
“Through the Thou a person becomes I” 
 
 
To Jani, for providing a healing space 
 
 
To Bertram Karon and Steven Copeland, 
















I would like to thank Drs. Leonard Handler, Robert Wahler, Lowell Gaertner and 
Stan Lusby for serving on my doctoral committee and guiding me through this exciting 
and challenging process. In particular, I greatly appreciate Dr. Handler’s mentorship in 
learning how to contact even the most disturbed patients in psychotherapy and through 
assessment. This project would not have come into being if it were not for his support of 
my clinical and empirical interest in working with the severely ill. A special thanks to 
Bertram Karon and the Michigan State Psychotherapy Project archives for providing 
access to the rich data set used in this dissertation project. I’d like to warmly thank Drs. 
Kathryn White, Jeffrey Slavin, Jack Barlow, and Marc Castellani for being there – 
internally and externally – when engagement with their wisdom, friendship and 
composure was so greatly needed. I’d also like to thank Drs. Mark Hilsenroth and 
Michael Nash for providing inspiring models of expert psychodynamically-oriented 
researchers. I am grateful for the fine work and passion of the International Society for 
the Psychological Treatment of Schizophrenia-U.S., especially Drs. Brian Koehler and 
Ann-Louise Silver whose contributions to my education have been substantial. Further 
acknowledgment goes to Chad Sims, Angie Kinney, and Jared Defife without whom the 
empirical component of this dissertation project would not have been possible. To all 
those I have never met yet continue to inspire and guide: Martin Buber, Don Mattingly, 
Paul Celan, Franz Kafka, Rainer Maria Rilke, James Blount, Abraham Joshua Heschel, 
Amos Oz, Andrew Hyra, Heinz Kohut, Harold Searles, Frieda Fromm-Reichmann, Harry 














Since the early 1950s, biopsychiatric conceptualizations have dominated 
empirical, theoretical and therapeutic efforts to understand the treatment of 
schizophrenia. The contemporary preeminence of biopsychiatric conceptualizations of 
schizophrenia have overshadowed other perspectives that might contribute fruitfully to 
our capacity to understand and aid individuals suffering with this devastating emotional 
disorder. The origin of modern biopsychiatric conceptualizations is deconstructed by 
illuminating the non-epistemic underpinnings of Emil Kraeplin’s dementia praecox 
concept, which is the forerunner of the modern schizophrenia construct. Two widely held 
assumptions of the biomedical model, namely: 1) that schizophrenia is a degenerative, 
organic brain disease; and 2) that neuroleptic medications are the most effective and 
safest treatment of schizophrenia are empirically reviewed. Psychodynamic theory and 
therapy alternatives are also reviewed empirically and theoretically. The comparative 
effectiveness of Psychodynamic Psychotherapy-only (n = 9) and Medication-only (n = 
12) was investigated using an experimental design (Karon & VandenBos, 1981). All 
patients were administered the Thematic Apperception Test (TAT) at pre- and post-
treatment (20 months). Westen’s (1995; Hilsenroth, Stein, & Pinsker, 2004) Social 
Cognition and Object Relations Scale (SCORS) was used to rate the pre- and post-
treatment TAT narratives in order to assess changes in the cognitive and affective aspects 
of patients’ object relations throughout treatment. Jacobson and Truax’ (1991) Clinical 
Significance methodology was used to detect clinically significant change for each 
individual patient. Results show the SCORS is a reliable and valid instrument for use 
with a schizophrenia sample. Treatment outcome results suggest that patients receiving 
 v
psychodynamic psychotherapy exhibit clinically significant change in a variety of object 
relations domains when assessed at the group and individual levels. Comparative 
analyses indicated that Psychodynamic Psychotherapy-only patients outperformed 
Medication-only patients in regard to changes in a variety of object relations domains. 
Medication-only patients did not outperform Psychodynamic Psychotherapy-only 
patients in any domain of object relations. Significantly more Medication-only patients 
exhibited clinical regression compared to patients receiving psychodynamic 
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“All I want to do is to follow the advice given by Elihu, the son of Berachel of old, who said, ‘I 
will speak that I may feel relief’; for there is a redemptive quality for an agitated mind in the 
spoken word.” 
     -J.B. Soloveitchik 
     in The Lonely Man of Faith  
 
Despite serious empirical and clinical questions regarding diagnostic reliability 
and validity (Blom, 2003; Boyle, 2002; Whitaker, 1992), the Diagnostic and Statistical 
Manual-IV (DSM-IV; American Psychiatric Association [APA], 1994) provides the most 
widely accepted diagnostic criteria for schizophrenia. Due to the wide availability of the 
DSM-IV only the most essential characteristics of the schizophrenia diagnosis will be 
discussed below. 
 The most characteristic criteria necessary to receive a diagnosis of schizophrenia 
are the presence of two (or more) of the following symptoms, each present for a 
significant portion of time during a one month period: 1) delusions; 2) hallucinations; 3) 
disorganized speech; 4) grossly disorganized or catatonic behavior; and/or 5) negative 
symptoms (Criterion A). It is important to note that only one Criterion A symptom is 
required if delusions are bizarre, hallucinations consist of a voice keeping a running 
commentary on the person’s behavior or thoughts, or two or more voices are conversing 
with each other. Bizarre delusions are defined as anything that is entirely improbable. For 
example, a young man of twenty-one fears an alien with three heads is tracking his every 
movement because his patterns of gesticulation are the key to unlocking the mysteries of 
the universe. Importantly, a delusion that is fantastic but possible is not bizarre. For 
example, a schizophrenic man of thirty-five fears the FBI is spying on his family. This is 
unrealistic but nonetheless possible since the FBI could spy on someone with the 
 1
appropriate motivation, whereas three headed gumshoe aliens are not in the realm of 
possibility. 
Characteristic symptoms fall into two broad categories: positive and negative. 
Simply, positive symptoms appear to reflect an excess or distortion of normal functions, 
whereas negative symptoms appear to reflect a diminution or loss of normal functions. 
The positive symptoms (Criteria A1-4) include distortions in thought content (delusions), 
perception (hallucinations), language and thought processes (disorganized speech) and 
grossly disorganized or catatonic behavior. Negative symptoms (Criterion A5) include 
restriction in the range and intensity of emotional expression (flattening), diminishment 
of fluency and productivity of thought and speech (alogia), and greatly decreased degree 
of goal-directed behavior (avolition).  
Concordant with these primary symptoms are distinct and pervasive 
social/occupational dysfunction (Criterion B). Continuous signs of the disturbance must 
persist for at least six months which must include at least one month of symptoms that 
meet Criterion A (Criterion C). The remaining criteria include: exclusion of 
schizoaffective disorder and/or mood disorder  (Criterion D), exclusion of a substance 
abuse or general medical condition (Criterion E), and if there is a history of a pervasive 
developmental disorder (e.g., autism) a diagnosis of schizophrenia is made only if 
prominent delusions or hallucinations are also present for at least one month (Criterion 
F). DSM-IV recognizes 7 subtypes of schizophrenia (Paranoid, Disorganized, Catatonic, 
Undifferentiated, Residual, Schizophreniform, and Schizoaffective; see APA, 1994, pp. 
286-295).  
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Demographically, in the United States (U.S.), the onset of psychosis commonly 
occurs between the ages 17 to 27 for males and 20 to 37 for females. In the U.S., race 
does not seem to impact the distribution of schizophrenia. Schizophrenia affects 1-1.5% 
of the U.S. population and this percentage is consistent worldwide (Silverstein, 
Spaulding, & Menditto, 2006). Consistently, schizophrenia is among the top 10 leading 
causes of disability in adults both in the U.S. and worldwide, therefore representing a 
disorder of significant fiscal importance. In the U.S., nearly 80% of persons with 
schizophrenia are unemployed and many of the remaining 20% are significantly under-
employed indicating overall a crippling social and vocational condition. In the U.S. up to 
13% of people with schizophrenia commit suicide. 
Of particular relevance to this study, almost 100% of the people diagnosed with 
schizophrenia in the United States have been or will be treated with psychotropic drugs 
(Jackson, 2005). A very small percentage of people suffering from this mental illness 
receive psychotherapy and an even smaller percentage will be offered psychodynamic 
psychotherapy, despite evidence that a variety of forms of psychotherapy are effective for 
psychotic disorders such as schizophrenia (Jackson, 2005; Karon, 1989; Whitaker, 1992).  
An honest review of the empirical and clinical literature is imperative so that 
psychiatry and psychology can develop the most effective treatments for people suffering 
from schizophrenia. Such an exploration might inevitably lead to a major transformation 
whereby the mental health field can begin speaking about catharsis and recovery, as 
opposed to mere management and containment of schizophrenia. The latter pessimism is 
a reflection of the non-empirically supported notion that schizophrenia is solely an 
irreversible, organic, degenerative brain disease (Harding & Zahniser, 1994; Harman, 
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2003, Siebert, 1999). This unfounded assumption drives medication-only treatments 
despite the fact that there are no replicable studies to validate this widely held idea. In 
fact, as will be shown, there are a multitude of studies investigating the impact of 
untreated schizophrenia, as well as longitudinal outcome studies refuting the degenerative 
assumption. 
Considering the monolithic medication approach to schizophrenia one would 
suspect that ample evidence exists regarding the physiological etiology of this alleged 
brain disease. However, laboratory findings diagnostic of schizophrenia are inconsistent 
and, more importantly, confounded by the significant physiological side-effects of an 
individual’s past and present use of neuroleptic medications (APA, 1994; Harding & 
Zahniser , 1994; Harman, 2003; Jackson, 2005; Sullivan, Owen, O’Donovan, & 
Freedman, 2006; Warner, 2004). Thus, the idea that schizophrenia is a purely 
biologically-derived, degenerative brain disease is “totally unfounded and unsupported by 
scientific evidence…Rather the basis of the appellation ‘brain disease’ is based on 
theories of possible etiologies of those diagnosed with schizophrenia.” (Harman, 2003, p. 
240). The APA-sponsored DSM-IV honestly writes, “…laboratory findings may also be 
noted as a complication either of schizophrenia or of its treatment” (APA, 1994, p. 306). 
In fact, the side-effects of neuroleptic treatments are so hazardous that the DSM-IV has a 
diagnostic category known as “Neuroleptic induced disorders” (APA; pp. 735-805). As 
the DSM-IV acknowledges, an additional problem is that there are no replicable studies 
identifying the biological correlates of schizophrenia using drug virgins (APA, 1994). 
‘Drug virgins’ are defined as individuals free of the damaging and confounding side-
effects of antipsychotic medications. When drug virgin patients are investigated, the 
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results indicate that medications rather than the illness itself are generally responsible for 
any brain differences between schizophrenics and normals (e.g., Gur et al., 1998). The 
overt contradiction between what is known about schizophrenia and how it is treated 
should not be overlooked here. Although the APA-published DSM-IV admits that there 
are no studies that document the biological underpinnings of schizophrenia, it is this very 
same body that advocates medication as the primary and, in general, sole treatment 
approach.  
Although some degree of genetic effect is likely present in the development of 
schizophrenia, the genetic contribution is undoubtedly non-linear and far more limited 
than originally suspected. Harvard geneticist Richard Lewontin (2000) comments on the 
neurogenetic reductionism fueling the assumption that genetic variation can explain all 
forms of human illness, he writes,  
 The search for genetic variations is a major preoccupation of medical  
research [but]…it is bad biology… There exists, and has existed for a long time, a 
large body of evidence that demonstrates that the ontogeny of an organism is the 
consequence of a unique interaction between the gene it carries, the temporal 
sequence of external environments through which it passes during life, and 
random molecular interactions within individual cells. It is these interactions that 
must be incorporated into any proper account of how an organism is formed (pp. 
17-18; my emphasis).  
Indeed, what etiological evidence does exist point to poly-genetic factors of low to 
moderate effect in a dose-response, non-linear relationship with a variety of high-risk 
environmental factors such as deviant communication between children and caregivers 
 5
(Wynne & Singer, 1963), disturbed interactions within a family (Alanen, 1980, 1997; 
Tienari et al., 1985), childhood trauma (Read, Perry, Moskowitz, & Connolly, 2001; 
Read & Ross, 2003), and prenatal and perinatal factors (Gilmore & Murray, 2006).   
Thus, assumptions regarding the linear biological or genetic correlates of schizophrenia 
are, at least for now, empirically and theoretically untenable. Koehler (2006) more 
concisely describes the complex thinking needed if we are to develop a more 
sophisticated view of schizophrenia development and treatment,  
…reductionism in psychiatry is what it has always been, a costly and erroneous 
shortcut to the comprehensive understanding and treatment of complex mental 
disorders which arise from complex non-linear interactions between genes, brain, 
mind (which included multiple factors at the level of the individual and the 
family), as well as the socio-cultural surround…(p. 3).  
By taking seriously the disconnect between how little is known about the etiology of 
schizophrenia and the rigid certainty with which medical treatments are offered, it is the 
stated intention of this dissertation project to arrive at an empirically and theoretically 
sober understanding of current psychotherapeutic and psychopharmacological treatment 
practices. This will be accomplished by investigating five interrelated sections.  
Section I: Emil Kraeplin, Degeneration Theory, and Philosophical Realism. Since 
neuroleptic treatments overwhelmingly dominate the modern treatment approach for 
schizophrenia, it is helpful to understand the epistemology of the schizophrenia construct 
that continues to impact biological conceptualizations and treatment decisions. This 
section will focus on two of the non-epistemic philosophical underpinnings of the 
 6
schizophrenia construct originally developed by the founding father of modern psychiatry 
Emil Kraeplin: degeneration theory and philosophical realism.  
Section II: The Empirical Validity of the Degenerative Disease Construct. 
Philosophical deconstruction of a prevailing construct does not invalidate its core 
assumptions. That is, simply because modern biopsychiatric conceptions of schizophrenia 
are substantially influenced by a multitude of non-epistemic factors does not necessarily 
mean that the illness is not biologically-based and degenerative. That being said, if the 
biopsychiatric notion that schizophrenia is a chronic degenerative brain disease resulting 
in a psychotoxic impact on the brain is accurate, then naturally most if not all cases of 
schizophrenia (treated and untreated) would ultimately leave a person significantly 
incapacitated ad infinitum. After all, biological medication treatments are only designed 
to slow this allegedly inevitable process and mask rather than cure the most striking 
features of the illness (i.e., positive symptoms such as hallucinations). To determine the 
validity of the degenerative/psychotoxic assumptions of biopsychiatry, I will review two 
interrelated empirical questions: 1) does the duration of untreated schizophrenia predict 
greater severity of illness, poorer overall outcome, and psychotoxic brain damage; and 2) 
are there longitudinal studies that report any degree of significant improvement or 
recovery for persons diagnosed with schizophrenia?   
Section III: The Effectiveness and Safety of Neuroleptic Medications. For the 
reason that neuroleptic medications are used as the frontline - and usually only - 
treatment of schizophrenia (Breggin, 1991; Karon, 1989; Whitaker, 2002, 2005), it is 
imperative to summarize the empirical literature that has investigated the effectiveness 
and safety of these medications. The effectiveness of neurolepetc medications will be 
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evaluated on four fronts by: 1) presenting data regarding the effectiveness of older 
(typical) and newer (atypical) neuroleptic medications (Table 1 lists all of the 
medications still commonly used to treat schizophrenia; Appendix A1); 2) presenting a 
critique of the methodological limitations inherent in the Food and Drug Administration 
(FDA) and non-FDA randomized control medication trials (RCT) specific to 
schizophrenia research2; 3) summarizing the most recent, large-scale, naturalistic study 
investigating the comparative effectiveness and safety of the newer versus older 
neuroleptic drugs; and 4) presenting the variety of side-effects resulting from exposure to 
typical and atypical neuroleptic medications.  
Section IV: The Effectiveness of Psychodynamic Psychotherapy of Schizophrenia. 
This section will explore the empirical effectiveness of the psychodynamic treatment of 
schizophrenia. There is a growing body of empirical and theoretical literature of effective 
non-psychodynamic approaches to schizophrenia (e.g., cognitive-behavioral therapy) that 
will not be addressed here. Focus on psychodynamic treatment will be primary because 
this is the modality used by the therapists that treated the patients in the empirical 
component of this dissertation project.  
Section V: Pre- to Post-Treatment Change in the Object Relations of 
Schizophrenic Patients. Data for this project were generously provided by the Michigan 
State Psychotherapy Project archives (Karon & Vandenbos, 1981). The empirical section 
of this dissertation project applies a modern measure of object relations to pre- and post-
treatment Thematic Apperception Test (TAT; Murray, 1943) narratives of schizophrenic 
                                                 
1 All tables are located in Appendix A 
2 The critique presented below is not intended to be a general critique of RCT methodology. Rather, it is a 
critique specific to the methodology of schizophrenia drug research.  
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patients divided into two groups: 1) individual psychodynamic psychotherapy without 
medication (Psychotherapy; n = 9); and 2) routine medication-only (typical neuroleptics 
only) treatment (Medication; n =12) to determine clinically significant treatment effects 
within- and between-groups. That is, it is the primary purpose of this study to investigate 
two particular research questions: 1) can individual psychodynamic psychotherapy for 
schizophrenia - without any medication - result in positive outcome in terms of object 
relations; and 2) what is the comparative effectiveness of medication-only versus 
individual psychodynamic psychotherapy-only treatment of schizophrenia?  
The experimental design utilized in the original study conducted by Karon and 
Vandenbos (1981) called for the selection of schizophrenic patients to be assigned on the 
basis of a random number table to one of three treatments: 1) psychotherapy without 
medication (Psychotherapy-only A); 2) psychotherapy with adjunctive medication 
(Mixed B); and 3) routine hospital treatment consisting primarily of phenothiazines (i.e., 
typical neuroleptics; Medication-only C). The adjunctive medication provided to 
individuals of the Mixed Group (B) was discontinued after the first few weeks of the 
study. Overall, 36 patients were evenly distributed among the three treatment groups. 
Due to incomplete data for the Mixed group (B) this cohort has been removed from the 
current study. Although this is an unfortunate loss of potentially useful and interesting 
data, the primary and unique aspect of the current experiment is the assessment of a 
completely non-medicated group. That is, while there are studies exploring mixed 
treatment approaches (see Gottdiemer & Haslam, 2002) there are, as far as could be 
determined, no published U.S.-based studies in the last 25 years that utilize a fully non-
medicated group.     
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Karon and Vandenbos’ (1981) administered four assessment instruments 
measuring patients’ thought disorder and two personality projective instruments at pre- 
and post-treatment to all patients. Number of days spent in the hospital and a blindly 
rated clinical status interview were also used as measures of outcome. At the conclusion 
of their 20-month investigation researchers found that patients receiving psychotherapy 
(Groups A & B) significantly outperformed individuals receiving medication-only 
(Group C) on three of the four instruments assessing patients’ thought disorder, on the 
clinical status interview, and number of days spent in the hospital due to mental 
dysfunction. On the fourth measure of thought disorder differences between the 
psychotherapy and medication-only patients nearly reached significance (p = .07), again 
favoring the psychotherapy patients. Individuals of the medication-only group did not 
fare better in any area assessed.  
One of the two measures for which there was no significant finding was the TAT. 
During the time period Karon and Vandenbos collected and reported their findings there 
were no reliable and valid narrative measures to adequately assess TAT protocols. In lieu 
of a reliable and valid measure Karon and Vandenbos applied a global score to pre- and 
post-treatment TAT protocols to assess general health-sickness in a manner akin to the 
three Axis V scales described in the DSM-IV (APA, 1994). As a result, they were unable 
to fully tap the information inherent in the pre- and post-treatment TAT protocols. This 
study corrects this original deficiency by using Westen’s reliable and valid Social 
Cognition and Object Relations Scale (SCORS; Westen, 1995; Hilsenroth, Stein, & 
Pinsker, 2004) to score the original pre- and post-treatment TAT protocols for both 
groups.   
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The SCORS was used to measure the object relations and social cognitive 
functioning of patients from their pre- and post-treatment TAT protocols. Westen and 
Gabbard (1999) defined object relations broadly as a person’s enduring patterns of 
interpersonal functioning in intimate relationships, beginning - but not concluding - with 
the mother/infant dyad. Therefore, object relations are the interpretation and mental 
internalization of relationships between the self and other people or objects (i.e., places, 
things, constructs). As Summers (1994) states, “[T]he structure of the self is formed from 
the internalization of early attachment relationships and is based on the symbolic 
meaning the child gives to its early object ties. In this sense, these early object relations 
not only endure, but define the sense of self and influence later relationships with others” 
(p. 350). As will be shown throughout this dissertation project, schizophrenia is far more 
than a biochemical illness defined by disturbed visual and auditory perceptual processes. 
Rather, it is a mental disorder driven by core disturbances in a person’s capacity to relate 
to his or her self and others; and, even the most bizarre of the psychotic hallucinations 
and delusions, as well as massive social isolation common to schizophrenic patients, are 
best understood in the framework of a grave interpersonal disturbance. As such, 
measuring an individual’s object relations pre- and post-treatment is essential to assessing 
the degree and quality of therapeutic relief provided by any given treatment.  
The SCORS is a narrative-based object relations measure designed to assess a 
variety of dynamic personality features beyond the overt symptomatic presentation of the 
patient (see Methods below). As far as can be discerned from the extant literature, the 
current investigation was the first to apply the SCORS to a strictly schizophrenic sample, 
thus providing important reliability and validity information for a psychotic population. 
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Assessing observer-rated object relations adds incrementally to the overwhelming 
majority of the schizophrenia outcome literature that are generally limited to assessment 
of overt psychiatric symptoms and/or drug tolerability (e.g., Lieberman et al., 2005). 
Furthermore, the current analysis is unique to the extant literature in that it uses an 
experimental design that includes a fully non-medicated group. Such studies are 
relatively rare and generally considered irresponsible “malpractice” (Karon, 2003, p. 96) 
due to the non-empirically supported assumption that medication treatments are the only 
viable treatment for schizophrenia (Bola, 2006). In fact, despite considerable counter-
evidence to be provided below, the schizophrenia Patient Outcome Research Team 
(PORT; Lehman & Steinwachs, 1998) referred to psychodynamic psychotherapy as 
“harmful” for patients suffering with schizophrenia (p. 8). The PORT is regarded as one 
of the authoritative voices in the treatment of schizophrenia and its conclusions are 
accepted as empirical fact despite its evident distortion of the psychodynamic treatment 
literature (see for a critique of the PORT Gottdiener & Haslam, 2003; Silver, 2003; ver 
eecke, 2003). Considering the PORT study’s comments neglectful of available empirical 
evidence, hypotheses for the current study include: 1) The SCORS will exhibit 
satisfactory reliability and validity for use with a strictly schizophrenia sample; 2) 
Psychotherapy-only patients will not clinically regress, rather, they will exhibit clinically 
reliable improvement in their object relations; and 3) the object relations of the 
Psychotherapy-only patients will exhibit significantly greater clinically reliable change 
compared to the Medication-only patients due to psychodynamic psychotherapy’s 
explicit emphasis on past and present interpersonal functioning.   
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Section I: Emil Kraeplin, Degeneration Theory, and Philosophical Realism  
 Emil Kraeplin, born in 1856, is considered the father of modern descriptive 
psychiatry and founder of the ‘dementia praecox’ concept that was later changed to what 
we now term ‘schizophrenia’ (Bleuler, 1911). Kraeplin’s professional life was committed 
to the classification of mental phenomena. His nosological thinking focused almost 
exclusively on the relationship between manifest symptoms and the developmental 
course and outcome of mental disorders. Kraeplin’s ideas are still highly influential today 
(Gottesman, 1999; Harman, 2003).  
Kraeplin required an overarching organizing principle with which to ground his 
observations, a principle that would provide a classificatory framework useful for 
categorizing the complexity of observed mental phenomena. He had little to draw on 
from previous research since psychiatry itself had only existed as a medical profession 
since the 1850s (Gottesman, 1999). In fact, the first three editions of his masterwork, 
Compendium der Psychiatrie, made only incremental contributions to the field of 
descriptive psychiatry and they were received indifferently by the psychiatric 
establishment of the time. However, Kraeplin’s fourth edition published in 1893 made the 
first imprint of what would become a lasting mark on modern psychiatry.  
In this fourth edition, Kraeplin operationalized a unique organizing principle to 
ground his observations of a wide array of mental phenomena: the syndrome-course unit 
Blom (2003). Adoption of this umbrella notion allowed Kraeplin to distinguish symptom 
clusters with a relatively good outcome from those with a poor outcome. As such, he 
introduced outcome as a diagnostic criterion. As will be seen, this move certainly had 
practical advantages for his capacity to organize ever-greater numbers of mental 
 13
phenomena, but was void of empirical backing and beholden to a variety of non-
epistemic assumptions that have profoundly shaped the modern biopsychiatric conception 
of schizophrenia.  
 The term ‘dementia praecox’ first appeared in the fourth edition of Kraeplin’s 
Compendium in 1893. This publication is considered the birth of the modern 
schizophrenia concept. Using the notion of the syndrome-course unit, Kraeplin 
categorized dementia praecox under the heading, ‘mental degenerative processes’, 
thereby suggesting that its outcome was inherently poor. On what basis did Kraeplin 
make this classification? This is a question often left unanswered despite its monumental 
significance for contemporary research and treatment strategies. In his postmodern 
deconstruction of schizophrenia, Blom (2003) attempts to answer this question by 
assessing the role of degeneration theory in Kraeplin’s thought, he writes,  
Degeneration [theory] referred to a supposed hereditary predisposition to all kinds 
of misery, such as physical and mental disease, addiction, moral decay, sexual 
aberrations, and criminal behavior. In Kraeplin’s view, mental disorders 
originated from some inherited degenerative trait or from an external cause - or 
possibly from both (p. 55). 
In Kraeplin’s writings, “external cause” was meant to capture the effects of brain trauma, 
epidemics, pre-natal trauma, etc. That is, they were not meant to reflect the vicissitudes of 
psychosocial life, a factor Kraeplin seemed to deem generally irrelevant. As is evident in 
Kraeplin’s primary writings, he organized almost all mental phenomena based on 19th 
century degeneration theory though he never explicitly stated this as such. Rather, he 
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cited the more scientific sounding ‘syndrome-course unit’ as his primary organizing 
principle.  
 In the 19th century, degeneration was deemed the polar opposite of successful 
social and physical evolution. Kraeplin borrowed heavily from the degenerationist idea 
that certain patterns of the brain were remnants of our ancient evolutionary past or in 
Kraeplin’s words, “tribal history” (as cited in Blom, 2003, p. 75). Degeneration theory 
argues that such maladaptive patterns manifest as regressive cognitive and behavioral 
functioning. As Blom (2003) notes, this theory held wide appeal in 19th century Europe 
because it gave society a framework for explaining modernity’s budding “misfortunes 
and wickedness” (p. 75). Anthropologist R. Barrett’s (1996) comments illuminate the 
prolific nature of degenerationist ideas in Europe at this historical moment,   
Thus in their physiognomy and behaviour [sic], criminals and the insane were 
likened to primitives… The urban poor, including prostitutes, criminals, and other 
immoral types, were degenerates, exemplified by their low brain weights, 
protruding jaws, and misshapen skulls… Degeneration theory had to do with the 
proper place of races and classes… Most importantly, it was used to explain the 
apparent increase in the rates  of mental illness and incurability… (p. 67).  
Kraeplin’s enthusiasm for degenerationist thought was translated into an uncritical use of 
this non-epistemic construct throughout the development of his dementia praecox 
concept (Blom, 2003). For example, Kraeplin observed, “About 75% of the cases that go 
to mental asylums appear to reach the higher grades of dementia. The patients gradually 
sink deeper and deeper, become dull and apathetic and lose all understanding for those 
around them” (1899, p. 117). These observations led Kraeplin to consider schizophrenia 
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as degenerative in nature. Unintentionally, Kraeplin’s a priori commitment to the 
biological notion of degeneration prevented him from considering the effects of isolation, 
maltreatment, the cruel experimental treatments frequently used in the institutions of the 
19th century, and the social stigma insane people endured at the time (Gilman, 1982), all 
of which undoubtedly affected clinical course. Despite the fact that Kraeplin himself 
observed that between 13-20% of these patients improved almost completely, he still 
spoke monolithically of a degenerative trait inherent in schizophrenia. Kraeplin could not 
explain this phenomenon of recovery. Interestingly, modern psychiatry has found a 
solution to Kraeplin’s dilemma by often dismissing improved and recovered patients as a 
result of misdiagnosis (Karon, 2003; Whitaker, 1992). That is, if a person with 
schizophrenia exhibits significant improvement, today or yesteryear, it is assumed that 
they were never truly schizophrenic because, the circular logic concludes, schizophrenia 
is a degenerative disease. Such contemporary proclamations indicate the degree to which 
Kraeplin’s degenerative emphasis has remained. 
 As can be seen from the above discussion, prior to philosophical post-modernism 
it was uncommon for scientists to introspect about non-epistemic influences informing 
their work. After all, science, unlike religion and philosophy, was deemed a mode of 
investigation exempt from external contaminants and conceived as ‘truly objective’. Such 
thinking formed the basis of Kraeplin’s nosological creations and by default allowed him 
to feel confident that dementia praecox existed completely independent of his chosen 
organizing principles (i.e., syndrome-course unit and degenerative thought). Thus, 
Kraeplin deemed his description of individuals suffering with dementia praecox as a 
purely objective, in-the-world natural phenomenon open to scientific discovery. In 
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Hegelian terms, Kraeplin ‘removed himself from history’ and was able to see the world 
as it ‘truly’ exists. This is best known as philosophical realism and it too has had a 
profound impact on modern biopsychiatric conceptions of schizophrenia (Blom, 2003). 
Philosophical Realism and Kraeplin’s Dementia Praecox Construct 
 Reliance on a realist position reifies schizophrenia as a natural disease entity that 
allegedly exists independent of the observer. A consequence of this in daily practice is 
the location of schizophrenia as a phenomenon to be examined outside the ebb and flow 
of common human experience and this has contributed to the suspension of curiosity in 
regard to the psychosocial and mentalized aspects of schizophrenia.  
 Positioning the observer outside the schizophrenic experience, whether the 
observer is a researcher or practitioner, accomplishes a few things. First, a concretized 
professional-patient hierarchy is constructed within which information flows uni-
directionally. Unto itself the professional-patient hierarchy is not detrimental and will of 
course exist in a situation when one person (the patient) seeks professional assistance 
from a trained other (psychotherapist, psychiatrist, etc.). However, it is my assertion that 
in the biopsychiatric model the doctor/schizophrenic split is hypertrophied due to its 
epistemological relationship to degeneration theory. That is, the patient is perceived as 
wholly different due to an inherent, archaic defect and the gap between schizophrenic 
patient and doctor will only widen as the degenerative trait runs its inevitable course. At 
best, this concretized hierarchical relationship results in the benevolent transmission of 
sympathy and basic human concern for the welfare of a suffering other. Yet, this 
hierarchy can also result in an institutionalized, unilateral mandate for compliance to en 
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vogue treatments. Modern mental health strategies for schizophrenia are a combination of 
these two outcomes, with an unfortunate emphasis on the latter as seen in many 
community agencies, day care treatment facilities, and group homes that impose 
medication compliance as a prerequisite for participation in their services (Karon, 2003). 
Medication non-compliance is interpreted as a ‘lack of insight’ on the part of the sufferer 
and is considered symptomatic of schizophrenia itself, rather than an expression of a 
person’s discomfort with side-effects, lack of drug effectiveness, or his or her demand to 
be treated as a person with a story to tell. In this sense, the schizophrenic person is 
regularly considered alien from prototypical insight common to the non-schizophrenic 
‘normal’. A person suffering with schizophrenia is viewed as lacking sentience and 
judgment - two definitive aspects of human-ness (Whitaker, 1992). The real-world 
consequence of this concrete split is that the schizophrenic is typically not considered 
integral to the development or modification of treatment strategies due to their assumed 
lack of insight.  
It is essential to note that the push for current medication compliance should not 
be interpreted as pure malevolence. Rather, it is an expression of the basic suppositions of 
biopsychiatry and is undoubtedly a well-meaning attempt by the majority of practicing 
psychiatrists to alleviate real human suffering. As such, it is all the more important for 
psychiatrists to understand the philosophical roots driving their clinical recommendations 
in order to develop the best possible approach to schizophrenic suffering. Understanding 
the realist underpinnings of biopsychiatric thought better equips one to comprehend the 
primacy of current neuroleptic treatment strategies. After all, if the origin of madness is 
genetic, internal to the sufferer from birth and is disconnected from the impact of human 
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interactions, then there is no reason to consider any treatments other than biologically- 
oriented ones. Further, and of particular relevance to this dissertation project, if a 
schizophrenic lacks the capacity for insight and is excluded from treatment decisions in 
general, psychodynamic psychotherapy will be the first to be labeled useless and 
ineffective. Indeed, marginalization of psychodynamic psychotherapy for the treatment of 
schizophrenia has been made official by the schizophrenia PORT recommendations 
(Lehman & Steinwachs, 1998) and others (Drake & Sederer, 1986), despite the lack of 
empirical backing for such assertions (Gottdiener & Haslam, 2002; Karon, 2003; ver 
Eecke, 2003).   
In concluding this philosophical section, Blom (2003) asserts that if current 
treatment approaches are to prove effective we must come to appreciate that the 
biopsychiatric notion of schizophrenia is “embedded in a matrix of scientific 
assumptions… guided by various culture-religious themes which dominated psychiatric 
thinking at the time [of its development]…and [has been] applied rather uncritically 
within the field…” (p. 9). Others have similarly investigated the scientific immaturity of 
the schizophrenia construct (Barrett, 1996; Bentall, 1998; Boyle, 2002; Warner, 2004). 
 
Section II: The Empirical Validity of the Degenerative Disease Construct  
If schizophrenia is a chronic, degenerative brain disease then naturally untreated 
schizophrenia would ultimately leave a person significantly incapacitated or dead. That 
is, for people suffering with schizophrenia it would be impossible to evidence signs of 
recovery. This is the idea driving the ‘management rather than catharsis’ strategy of 
medication treatments. However, what does the empirical literature have to say in regard 
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to the degeneration assumption? The answer can be found by asking two interrelated 
questions: 1) does the duration of untreated schizophrenia predict psychotoxic brain 
damage and/or poorer overall outcome as insisted by biopsychiatry; and 2) are there 
studies exhibiting any degree of significant improvement or recovery for persons 
diagnosed with schizophrenia?  
Duration of Untreated Schizophrenia: Psychotoxicity and Clinical Outcome 
Based on the biopsychiatric assumption that schizophrenia is a degenerative brain 
disease, biopsychiatry has concerned itself with the potential negative consequences of 
not treating schizophrenia as soon as possible. More specifically, it is a widely held belief 
that there is a “potential for untreated psychosis to be toxic to the brain” (Ho et al., 2003, 
p. 142). ‘Untreated psychosis’ is defined as the interval from first psychotic symptom to 
first treatment received. This question is very important to the main question of this 
dissertation project because the idea that psychosis left untreated by medications results 
in psychotoxic effects has raised ethical questions regarding the use of placebo controls 
in experimental drug trials (Craig et al., 2000). Similarly, and quite pertinent to this 
dissertation project, this notion has made inclusion of un-medicated schizophrenics in 
psychotherapy outcome studies subject to professional scorn and open to allegations of 
malpractice (Bola, 2006; Harman, 2003; Karon, 1989, 2003). Therefore, empirical 
resolution of this hypothesis is necessary for opening up new areas of psychotherapy 
research and expanding our perspective beyond a medication-only treatment approach.    
 Using structured interviews with schizophrenic patients and their families, as well 
MRI scan measurements, Hoff and colleagues (2000) found no significant correlations 
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between duration of untreated schizophrenia and severity of either cognitive or structural 
brain deficits. The authors conclude that an “uncontrolled toxic brain process [is an] 
unlikely” explanation of schizophrenic suffering (p. 1824).     
Using a variety of clinical measures to assess positive and negative psychotic 
symptoms, hopelessness, depression and anxiety, Craig and colleagues (2000) found that 
the duration of untreated schizophrenia was not significantly associated with severity or 
course of illness. In fact, the only statistically significant finding suggests that the earlier 
neuroleptic drugs are given, the more disturbed is the course and severity in regard to 
anxiety and depression. The authors conclude, “…our results failed to support the 
contention that a longer exposure to psychotic symptoms per se leads to a worse clinical 
outcome…[and]…do not support the suggestion of a psychotoxic effect exerted by 
prolonged exposure to psychosis” (p. 66).     
Utilizing advanced neurological measurement devices, Ho and colleagues (2003) 
found no significant correlation between length of untreated schizophrenia and 
neurocognitive functioning, brain volumetric measurements, or surface anatomy 
measurements. The authors conclude, “[Our results] suggest that large-scale initiatives3 
designed to prevent neural injury through early [medication] intervention in the pre-
psychotic or early psychosis phase may be based on incorrect assumptions” (p. 142).  
Perkins, Gu, Boteva and Lieberman (2005) performed a meta-analysis of forty-
three studies that investigated the impact of the duration of untreated schizophrenia. The 
                                                 
3 David (2004) addresses the economic and clinical wisdom of early, large-scale medication initiatives 
proposed by pharmaceutical companies. He states, “From a dispassionate appraisal of the research literature 
on the treatment of schizophrenia…If an early intervention service is to be useful, it should be at the 
population level, free of side-effects and inexpensive, and should not undermine clinical practice” (e.g., 
medication effects causing brain damage that makes quality, continuous treatment less effective and less 
probable; p. 111). 
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results of this meta-analytic study found no association between untreated schizophrenia 
with neurocognitive deficits or morphological changes in the brain, therefore refuting the 
idea that schizophrenia is a degenerative brain illness that has psychotoxic effects on the 
brain. Further, this meta-analysis did not bear out support for early medication 
intervention strategies since it found no association between the duration of untreated 
schizophrenia and symptom relapse. 
In their own review of the literature investigating the impact of the duration of 
untreated schizophrenia, Segarra and colleagues (2006) call for a redefinition and 
reconsideration of the assumptions that the duration of untreated schizophrenia 
deleteriously impacts clinical course, outcome, and brain structure. Based on this 
redefinition, the authors suggest that the design of early intervention programs reflect a 
heterogeneous rather than medication-only approach.   
Ayres and her Brazilian colleagues (in press) recently explored the impact of the 
duration of untreated schizophrenia in a large-scale São Paulo study. Using cognitive 
tests to assess working memory, attention, and verbal fluency of patients with first-onset 
schizophrenia the authors found no correlation between the duration of untreated 
schizophrenia and cognitive deficits.  
Of course, there are studies that find a relationship between the duration of 
untreated psychosis and clinical outcome (e.g., Clarke et al, 2006). After all, a person left 
to suffer without intervention – whether psychotherapy, medication, or both – may of 
course regress emotionally, though physiological damage appears unlikely. However, the 
majority of empirical evidence, including meta-analyses, refutes the 
degenerative/neurotoxic position. Rather, clinical regression is more likely to be 
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indicative of the existential, vocational, interpersonal and social alienation resulting from 
the onset of a frightening schizophrenic condition, rather than the supposed neurotoxiciy 
of schizophrenia without medication treatment (Karon, 2003). Concerning the neurotoxic 
assumption McGlashan (2006) asks and replies,  
[Does active psychosis] engineer brain cell death and deterioration? This 
hypothesis is currently popular as an explanation of the duration of untreated  
psychosis effect in early schizophrenia. The clinical and neurobiological evidence  
for its validity is…found wanting (p. 609).  
If anything, research is far more supportive of the idea that any significant neurological 
damage associated with schizophrenia is likely related to the medications used to treat the 
illness rather than the illness itself (APA, 1994; Breggin, 1991; Jackson, 2005; Whitaker, 
2002, 2005).  
Taking all this into consideration, it becomes all the more pressing to design 
early-intervention strategies based on research of all possible short- and long-term 
treatments (e.g., Alanen, 1997), rather than the false and draconian assumption that not 
using medications is psychically and organically destructive. That is, it is a primary, 
though false assumption of biopsychiatry that not administering drugs immediately is 
malpractice (Bola, 2006; Breggin, 1991).  
Of course, altruistically, psychiatrists want to minimize the subjective suffering of 
a person suffering from distressing symptoms. This is often stated as a further 
justification for the heavy reliance on psychiatric drugs, especially in the early period of 
the illness when the symptoms are particularly acute and disturbing for all involved. 
However, it is also false that only drugs can quickly minimize acute psychotic symptoms 
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such as frightening hallucinations and disorienting delusional constellations (Alanen, 
1997; Irwin, 2004a; Karon & Vandenbos, 1981; Harding & Zahniser, 1994; Paul, Tobias, 
& Holly, 1972; Paul & Lentz, 1977). Most recently, research emanating from the 
Scandanavian research of Alanen (1997) and Seikkula and colleagues (2000, 2003) speak 
to the empirical and clinical effectiveness of psychological intervention for early and 
acute positive symptoms with little to no use of neuroleptic medications.       
This entire discussion is relatively moot if there is little in the way of counter- 
evidence suggesting that there is real, long-term hope for people suffering from 
schizophrenia. A look at the body of longitudinal schizophrenia outcome studies adds 
additional empirical evidence that schizophrenia is not a chronic, progressively 
degenerative brain disease leaving such people without hope. 
Hope or Dread: Longitudinal Studies of Schizophrenia  
International and U.S.-based studies have investigated the degenerative 
assumption and they have found significant heterogeneity of outcome with a variety of 
received treatments (e.g., psychotherapy and medication) and even without treatment. I 
will provide an illustrative summary of the longitudinal evidence, but for the interested 
reader more extensive summaries of the longitudinal literature are available elsewhere 
(Leff, Sartorius, Jablensky, Korten, & Ernberg, 1992; Harrison et al., 2001; Hopper, 
Harrison, Aleksander, & Sartiorius, 2007; Hopper and Wanderling, 2000; Jablensky et 
al., 1992; Menezes et al., 2006). To more clearly understand the studies presented below 
it is important to hold in mind the operational definition of ‘recovery’ imparted by 
Harding and Zhasiner (1994) based on their summary of the longitudinal evidence,   
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The universal criteria for recovery have been defined as no current signs and  
symptoms of any mental illness, no current medications, working, relating well to  
family and friends, integrated into the community, and behaving in such a way as  
to not being able to detect having ever been hospitalized for any kind of 
psychiatric problems (p. 141). 
Clearly, the working definition of ‘recovery’ used in the following studies to which I will 
now turn is quite strict and highly relevant to day-to-day functioning.  
 In 1968, Murphy and Raman (1971) relocated 89 of 90 first-episode 
schizophrenics, admitted twelve years earlier to a hospital in the developing country of 
Mauritius. Patients and a person close to them throughout the intervening years were 
interviewed to determine current mental state and whether any relapses had occurred. 
Despite the fact that no neuroleptics were used in this developing nation at the time, 64% 
of the subjects were found to be currently free of symptoms of any kind. Of these 64%, 
only 8% went on to experience an additional psychotic episode at some point. Not only 
did the lack of early medication do no harm to these patients, this fact might actually help 
explain why these relatively low relapse rates are superior to relapse rates in the 
developed world where neuroleptics are widely used (Hopper, Harrison, Aleksander, & 
Sartiorius, 2007; Irwin, 2004a; Menezes et al., 2006; Warner, 1985).   
 Following discharge from a psychiatric hospital, Bleuler (1978) maintained 
contact with 208 of his schizophrenic patients for 23 years in Zurich, Switzerland. In his 
analysis of first-admission patients 23% had achieved full recovery, 43% were 
significantly improved, and 34% had little to no change. Although Bleuler unfortunately 
did not provide statistical results across treatment interventions, his treatment approach 
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minimized the use of biological treatments and strongly favored psychosocial approaches 
for those patients he followed clinically.  
 Tsuang, Woolson, and Fleming (1979) reported on 186 of 200 people admitted to 
an Iowa psychiatric hospital between the years 1934 and 1944. Structured interviews 
were completed with the patients and a first-degree relative of each. This study reported 
that 20% of the patients had little or no psychopathology at follow-up, 26% had mild 
symptoms but were generally doing well; and 54% had severe symptoms. Of the studies 
being reviewed this one provides the most pessimistic results and yet it still refutes the 
idea that schizophrenia is a progressively degenerative disease since almost half of the 
patients fared quite well after 35 years. 
 Huber, Gross, Schuttler, & Linz (1980) reported follow-up results on 502 first 
admissions diagnosed with schizophrenia in the 1950s. Face-to-face interviews were 
done with each patient. After an average of 22 years 22% had achieved a full recovery; 
43% were described as recovered with no psychotic symptoms; and 35% still endured 
characteristic schizophrenia symptoms. Were maintenance neuroleptics predominantly 
responsible for these positive results? The authors report that this was not the case. In 
fact, all of the individuals assessed to be among the healthiest 22% were not receiving 
neuroleptic medications.   
 Ciompi (1980) published approximately 37-year follow-up data for 289 first 
admission schizophrenic patients in Switzerland from 1900 onward. He found the course 
of the disease to be highly variable based on two hours of interviews with former patients 
and information received from family members and hospital files. He found that 27% had 
achieved a complete remission and 22% had only residual, non-psychotic symptoms. 
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That is, there is at least a 50/50 hope for successful outcome. The idea that schizophrenia 
is degenerative - and even more rapidly degenerative without neuroleptics - is specifically 
unsettled by Ciompi’s findings because more than 50% of the people in his cohort were 
diagnosed before the invention of any modern neuroleptic treatments. Ciompi concluded 
that the course of illness is most significantly impacted by “the expectations of the patient 
himself, his family, and surrounding persons which… seem often to act strongly as self-
fulfilling prophecies” (cited in Irwin, 2004a, p. 58) 
 In contrast to the poor outcome predicted by the biopsychiatric conceptualization 
of schizophrenia, Harding et al. (1987a, 1987b) found that the course of schizophrenia is 
significantly heterogeneous even for allegedly treatment-refractory, severely chronic 
schizophrenics. The authors provide long-term outcome data for 82 of 118 patients who 
were alive and interviewed 20-25 years after their entry into a Vermont psychosocial 
treatment project for chronic schizophrenia. In the mid-1950s when patients became part 
of the study, all of them were chosen to participate in a unique psychosocial rehabilitation 
program designed for patients previously deemed resistant to medication and other 
biological treatments. In fact, these were classic ‘back ward’ patients usually given-up-on 
as hopeless. Severity and chronicity is attested to by the fact that at the initiation of the 
rehabilitation/longitudinal study, the average patient had been ill for 16 years, was totally 
disabled for an average of 10 years, and had been continuously hospitalized for six years. 
Following the psychosocial rehabilitation program they were released to the community 
in the mid-to-late 1950s.  
 Interviews with participants and people close to them, as well as self-report and 
observational data measuring positive and negative symptoms, hospital records, social 
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and vocational functioning, number of hospitalizations, and overall quality of life, were 
all used to assess each patient’s current status. Harding et al. (1987a, 1987b) found that 
45% of the participants had no psychiatric symptoms and another 23% had some 
psychiatric symptoms, but none that were of a psychotic nature. That is, an astounding 
78% of the once biological treatment resistant, chronic, back ward patients fared very 
well 20-25 years later. The authors point to the comprehensive rehabilitation program as 
a potential reason for the success of 78% of this cohort. They specifically highlight the 
clinical utility of “…a pervasive attitude of hope and optimism about human potential, 
through the vision that, if given the opportunity, persons with mental illness could 
become self sufficient” (DeSistro, Harding, McCormick, Ashikaga, & Brooks, 1995, 
cited in Irwin, 2004a, p. 59). 
Ogawa and colleagues (1987) followed 140 people diagnosed with schizophrenia 
for 21-27 years. The study was designed as a relapse prevention study emphasizing 
neuroleptic treatment. At follow-up 31% of the 98 people researchers were able to track 
down were completely free of positive symptoms. The authors failed to report other 
significant areas that would speak to overall functioning, such as social and vocational 
functioning and negative symptoms. At follow-up, 65% of the patients were still taking 
neuroleptics and the suicide rate was a relatively high 11%, suggesting that this 
neuroleptic-only cohort did not fare favorably to other cohorts with less (or no) 
neuroleptic use.   
Harding (1995) summarized five U.S. and international longitudinal studies that 
followed schizophrenics for no less than 25 years. The authors found that 30% fully recovered 
in the long run and that 60-70% became self-sufficient. Importantly, results indicated no 
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further improvement in outcome since the introduction of neuroleptic medication. To the 
contrary, the long-term evidence suggests that outcomes have deteriorated since the 
introduction of medication-only clinical practices (Whitaker, 2002, 2005). In this regard, 
Harding (1995) made a startling observation: all of the patients who fully recovered were 
among the 50% of the original sample who reported to have stopped taking their medication. 
This could suggest that either the higher functioning patients felt freer to discontinue their 
medications - though this is not supported by the neuroleptic side-effect or outcome literature 
(Breggin, 1991) - or, more likely, that medication may preclude full recovery.  
Kua and colleagues (2003) published results of a 20-year longitudinal study 
carried out in Singapore. In this cohort, 44% of the participants were found to be in good 
to excellent psychological condition as measured by a global assessment scale. Of the 
total subject pool 48% were not receiving any neuroleptic medication and all of the 28% 
of the subjects with the highest level of functioning were among those not using 
neuroleptics. 
Menezes and colleagues (2006) reviewed 37 studies with a total of 4100 patients 
and a mean follow-up period of 35 months. Assessing a multitude of variables (e.g., 
country of study, psychosocial rehabilitation, age), they found that the sole use of 
neuroleptic medications was associated with worse outcome, whereas a combination 
approach (i.e., medications plus psychosocial rehabilitation) was a predictor of positive 
outcome. Unfortunately, psychotherapy-only treatments were not analyzed. 
Results of the World Health Organization (WHO) studies are extensively reported 
elsewhere (Harrison et al., 2001; Hopper et al., 2007; Hopper and Wanderling, 2000; 
Jablensky et al., 1992) and only a brief summary will be provided here. These studies 
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compare longitudinal outcome data in developed versus developing countries, using 
results from 2, 5, 15, and 25 years of follow-up data. The generally positive outcomes of 
people with schizophrenia in these studies provide additional evidence refuting the 
degenerative brain disease assumption. Importantly, the WHO-sponsored studies all used 
the same standardized outcome measures thus making the results highly generalizable. 
Quite pertinent for this dissertation project, the identical assessment methods provide 
fascinating data regarding the potential role of neuroleptic medications in the less 
favorable outcomes of the richer and allegedly more clinically advanced nations.  
In sum, 38% to 48% schizophrenic participants recovered across geographic 
locales. In poorer developing countries, participants were two to three times more likely 
to have good clinical outcomes. In regard to vocational functioning, people in poorer 
developing nations were three to four times more likely to be holding down a job 
(Hopper & Wanderling, 2000). Suicide rates were higher in the economically richer, 
more medication-reliant countries to the point that Harrison and colleagues (2001) 
recommend special suicide prevention programs be established in the richer developed 
nations. Follow-up research revealed that the poorer countries used significantly less 
medications (Jablensky et al., 1992). A striking example of the potential negative effects 
of medication is seen when comparing Agra, India to the far richer Aarhus, Denmark. In 
Agra, outcomes revealed that 63% of the participants had experienced complete 
remission, compared to only 17.5% in Aarhus.     
Thus, based on these international and U.S.-based longitudinal studies, the DSM-
IV statement (p. 282) reflecting a main supposition of biopsychiatry, “Complete 
remission (i.e., a return to full pre-morbid functioning) is probably not common in this 
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disorder”, is quite clearly empirically invalid. To conclude, it is worth citing the entirety 
of Harding and Zhasiner (1994) summarization of the longitudinal literature,  
…all of these studies have come to the same conclusion. The longer investigators  
followed an identified intact cohort (whether probands were in or out of 
treatment), the more pronounced the picture of heterogeneity  and improvement in 
function. These studies have found that half to two thirds of patients significantly 
improved or recovered, including some cohorts of very chronic cases…All of 
these investigators of long-term studies were trained in the older, more pessimistic 
conceptual models [i.e., Kraeplian degenerative brain disease model] and were 
surprised by their own findings. Because the myths have been repeated so often, 
they had become reified. The strong belief systems and resistance, encountered by 
these investigators, were caused by many factors and were not easily altered by 
one study. However, there is now a confluence of results (p. 141).  
These longitudinal studies provide significant hope that schizophrenia is not degenerative 
and that significant improvement and even recovery is quite possible, especially if 
medication treatments are not relied on as the sole or primary intervention.  
Simply because the biological and degenerative basis of schizophrenia is 
empirically unfounded does not necessarily translate into the ineffectiveness of 
medication treatments, though the poorer results of the richer, drug-reliant nations is not a 
good starting point to claim clinical effectiveness. That is, it still may be possible to 
successfully treat schizophrenia biologically even if it seems to be far more than just a 
biological disease. Let us now turn to the empirical literature investigating the clinical 
effectiveness of older and newer neuroleptic treatments. 
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Section III: The Effectiveness and Safety of Neuroleptic Medications 
The lack of evidence delineating the biological correlates of schizophrenia is not 
what most sufferers and their families and friends are informed about schizophrenia 
(Jackson, 2005). Breggin (1991) asserts that if patients were accurately informed of what 
psychiatry does not know, use of neuroleptic medications as the primary treatment would 
undoubtedly be questioned more deeply. Despite ever-ready proclamations of new 
miracle biological therapies that will solve the schizophrenic puzzle (e.g., insulin coma, 
lobotomy, electroshock, typical and atypical neuroleptics), none of these treatments have 
ever proven to be very effective (Whitaker, 2002, 2005). This review will begin with the 
older, typical neuroleptics. 
Effectiveness of the Typical Neuroleptics  
Epstein and colleagues (1962) investigated two groups of male, first-episode 
schizophrenics admitted to nine California State Hospitals during 1956 (n = 673) and 
1957 (n = 740). In 1956, 36% (n = 245) received neuroleptic treatment and 64% received 
no medications. In 1957, 48% (n = 355) of the 740 patients received neuroleptic drug 
treatment, compared to 52% (n = 385) who received none. The authors set out to 
investigate whether or not drug treatments shortened hospital stays. Defying the myth 
that neuroleptic drugs were responsible for ‘emptying the asylums’ (for a critique see 
Jackson, 2005; Harding & Zahniser, 1994; Whitaker, 2002, 2005), Epstein et al. found 
that schizophrenic patients treated with neuroleptics consistently – across nine different 
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sites – had significantly longer hospital stays compared to patients who did not receive 
medication treatment.  
In 1967, Schooler and colleagues published one-year follow-up results for their 
National Institute of Health project. The authors reported that the placebo group fared 
significantly better in terms of clinical symptoms and reduced rates of hospitalization 
compared to the three neuroleptic groups (chlorpromazine, fluphenazine, and 
thioridazine). Post hoc analyses revealed that following discharge, psychotherapy but not 
drug treatment, was associated with a higher level of social interaction and “a greater 
likelihood of a wage earner’s job being commensurate with his training” (p. 991). 
Further, rates of extrapyramidal side-effects were so severe in the chlorpromazine group 
that 37% of the patients had to be placed on antiparkinsonian chemical agents. As will be 
discussed below, these side-effects are largely permanent and at times fatal (Jackson, 
2005). Ultimately, rather than staying close to the data and concluding that people with 
schizophrenia do better with minimal neuroleptic exposure and/or psychotherapy-only, 
Schooler et al. concluded, “…because we were unprepared to recommend placebo as 
treatment of choice, we explored a number of possible variables that might have caused 
this” (cited in Irwin, 2004a, p. 61). The variable with which they hoped to explain these 
results is as follows: “when lack of improvement was observed in the patient [of the 
placebo group]…it may be that the staff responded to the ‘deprived’ [off medication] 
patient with some special quality of care” (p. 61). Needless to say, this conclusion is 
clearly hyperbolic and has no supporting empirical evidence. Even if it was a valid 
consideration it would actually only serve to advance the idea that human interactions are 
quite helpful for people suffering with schizophrenia (e.g., milieu therapy, individual 
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psychotherapy). Despite the explicit data, the author’s endorsement of neuroleptic 
medications in their concluding remarks provide us perhaps with an early, though 
instructive example, of the growing drug bias enveloping the field. 
Prien and colleagues (1968) investigated relapse rates among chronic 
schizophrenic patients over a six-month period when medications were withdrawn. 
Relapse was defined as a return of positive symptoms, extreme hostility and excitement, 
and/or threatening behaviors. Results were highly suggestive of a positive statistical 
relationship between medication use and relapse. That is, relapse rates were positively 
associated with neuroleptic medication dosage. Only 18% of the 65 patients receiving 
less than 300 mg/day of chlorpromazine relapsed following medication withdrawal. In 
contrast, of the 60 patients on moderate doses (300-500 mg/day) 47% relapsed; and, of 
the 53 patients on high doses (greater than 500 mg/day) 58% relapsed. The relapse rate of 
the low group was significantly different than the higher dose groups, although there was 
no significant difference found between the moderate and high groups. Most relative to 
this dissertation project is that of the 18 patients who were medication-free during the 
entirety of the study, only one subject (6%) relapsed over the next six months (6%). In 
sum, patients exposed to relatively less or no medications seemed to progress better in 
terms of positive symptoms and interpersonally, whereas exposure to medications 
precluded recovery and was associated with a greater potential for a return to psychotic 
functioning.  
In a subsequent study, Prien and colleagues (1971) replicated these results. Once 
again, those patients who did not receive any medications throughout the study fared 
significantly better. Only 2 of 30 patients who were on placebo at the start of the study 
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relapsed during the next 24 weeks (7%), whereas the rate of relapse in the drug groups 
were equal to the high rates found in the initial study. As a result, the authors concluded 
once again, "Relapse was found to be significantly related to the dose of the tranquilizing 
medication the patient was receiving before he was put on placebo - the higher the dose, 
the greater the probability of relapse” (p. 22). 
Another manner by which drug effectiveness can be determined is to compare 
pre-drug era with drug era outcomes. Bockoven and Solomon (1975) compared relapse 
rates of these two eras and found that 45 of the 100 randomly selected schizophrenic 
patients treated at the Boston Psychopathic Hospital in 1947 (the pre-drug era) had not 
relapsed in the five years following discharge. They also determined that 76% were 
successfully living in the community at the end of that follow-up period. However, of the 
100 randomly selected patients treated with medications in 1967 at a Boston community 
health center, only 31 remained relapse-free for the next five years. The authors found 
another troubling result from both a clinical and economic perspective: the medication 
treated patients were much more "socially dependent" compared to the un-medicated 
patients (i.e., in greater need of continuous state-supported day program treatment and 
social welfare benefits; p. 801). As a result, the authors concluded, “One unexpected 
finding of the comparison…is that these drugs might not be indispensable; in fact, they 
might actually prolong the social dependency of some discharged patients” (p. 796). 
Bockoven and Solomon’s results replicated larger sample studies in other cities 
confirming the growing suspicion that neuroleptic medications have significant 
limitations and dangers (Lehrman, 1960; Rachlin, Guritz, Lurie, & Rachlin, 1956).  
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 In their review of 13 neuroleptic treatment studies conducted between 1959 and 
1974, Gardos and Cole (1977) found a significant difference between the relative 
psychological health of relapsers depending on prior treatment with placebo or 
neuroleptics. They reported that people who relapse following drug exposure “are sicker 
than placebo relapsers” (p. 34). Due to the ‘medicate-first’ trend that had already 
entrenched itself within the field they wrote, “The suggestion that as many as half of 
schizophrenic patients might not be worse off their…medication…will surely meet with 
some raised eyebrows” (p. 34). Nonetheless, sticking close to their data they suggested, 
“The major principle we wish to stress is that every chronic schizophrenia outpatient 
maintained on an antipsychotic medication should have the benefit of an adequate trial 
without drugs” (p.35; my emphasis). The authors admonished psychiatrists to rethink 
current medication treatment strategies based not only on their specific relapse results, 
but also as a result of the permanent side-effects induced by these drugs.  
In the late 1970s, investigators helped explain existing evidence indicating that 
neuroleptic drugs cause a greater number of relapses, more regressed relapses, as well as 
poorer symptomatic and social outcome, by identifying the specific biological changes 
induced in the brain by neuroleptic medications. Chouinard and colleagues (Chouinard, 
Jones, & Annable 1978; Chouinard & Jones, 1980; Muller & Seeman, 1978) found that 
because neuroleptic drugs greatly decrease dopamine activity the brain compensates by 
becoming ‘supersensitive’ to dopamine by initiating a proliferation of dopamine 
receptors. As a result, when a patient stops taking dopamine blockers (i.e., neuroleptics) 
the brain is standing by with a far greater number of dopamine receptors to take in an 
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unusually high amount of dopamine and is therefore more biologically prone to 
psychosis. Chouinard (1978) remarks in this regard,  
Neuroleptics can produce a dopamine supersensitivity that leads to both 
dyskinetic (i.e., parkinsonian symptoms) and psychotic symptoms. An implication 
is that the tendency toward psychotic relapse in a patient who has developed such 
a supersensitivity is determined by more than just the normal course of the 
illness...[and] the need for continued neuroleptic treatment may itself be drug-
induced (p. 1410; my emphasis).  
Although psychiatrists often interpret the resurgence of psychotic symptoms as a return 
of the underlying schizophrenic brain disease and justification for lifelong neuroleptic 
management, this research conducted almost 40 years ago definitively showed that 
relapse is more related to drug-induced psychosis and not to any pre-existing 
schizophrenic deficit.  
Recently, Moncrieff (2006) summarized the literature exploring the relationship 
between drug exposure and ‘supersensitivity psychosis’ and confirmed these original 
studies of the 1970s. Moncrieff’s research, unlike the earlier studies, was able to include 
the newer generation of atypical neuroleptics in his review and found that they too are 
implicated in withdrawal-related psychosis. He writes, “It appears that the psychosis 
[evident upon relapse] may be a feature of drug withdrawal rather than the emergence of 
the underlying illness…” (p. 1). In other words, not only have neuroleptics been shown to 
be ineffective but also harmful above and beyond the well-known side-effects to be 
discussed below. These authors and others have also concluded that these supersensitivity 
 37
effects may be irreversible similar to tardive dyskinesia4 and other diseases (e.g., 
diabetes) produced by neuroleptic medications.  
Needless to say, the NIMH of the 1970s was startled by these findings that 
indicated the ineffectiveness and dangerousness of neuroleptic drugs. As a result, the 
NIMH was compelled to revisit whether or not schizophrenia could be successfully 
treated without drugs (Whitaker, 2002). Three NIMH-funded studies were conducted to 
explore this idea, all of which concluded that newly admitted schizophrenics fared better 
when treated without drugs.   
Carpenter, McGlashan and Strauss (1977) conducted the first of three NIMH 
studies. In this investigation, 49 schizophrenia patients were placed in an experimental 
hospital program that provided them with individual and group psychodynamic 
psychotherapy. These patients were compared to 73 schizophrenia patients receiving 
status quo drug treatments. Only 35% of the non-medicated patients relapsed within a 
year after discharge, compared to 45% of those treated with medication. The medicated 
patients also experienced more depression, blunted emotions, and retarded movements. 
An obvious but no less important observation was that the non-drug treated patients did 
not have to endure the many different marked physiological and emotional side-effects 
associated with neuroleptic use.  
 In a study of young male schizophrenics, Rappaport and colleagues (1978) found 
that patients treated without mediations while in the hospital and did not use medications 
during the three year follow-up period fared significantly better than 1) patients treated 
                                                 
4 Tardive dyskinesia is an irreversible physiological disease that results in involuntary and irregular muscle 
movements, usually, but not limited to, the facial region. Tardive dyskinesia and a number of other 
extrapyramidal side-effects associated with neuroleptic exposure will be discussed in greater detail below.    
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with medications while in and outside the hospital; 2) patients treated with medications 
while in but not outside the hospital; as well as 3) patients not treated with medications in 
the hospital but with medications during the follow-up period. That is, simply stated, the 
least possible exposure to medications the better, particularly in regard to symptoms, re-
hospitalizations, need for continued treatment and communal functioning. The authors 
concluded, “Routine and continuous use of [neuroleptics] may be contraindicated…” (p. 
107). Further, the authors make a statement one would be hard-pressed to find in the 
current mainstream biopsychiatric literature, “The findings underlie the need for further 
study of how to utilize antipsychotic medication more selectively in the treatment of 
schizophrenia” (p. 100). 
 In the last of the three NIMH studies, Matthews and colleagues (1979) reported 
that patients treated without neuroleptics in a non-professionally staffed milieu setting 
fared better than patients treated with medically trained doctors administering 
neuroleptics. By six weeks, the two groups fared equally well in regard to 
psychopathology, refuting the claim that neuroleptics are far superior for short-term 
decreases in acute positive symptoms. Over the two-year follow-up period, the un-
medicated patients had a healthier level of social functioning, reported less subjective 
distress, and were incurring less treatment costs compared to the drug group. These 
results have been replicated by U.S. and international researchers (Cullberg, 1991; Karon 
& Vandenbos, 1981; Lehtinen, Aaltonen, Koffert, Rakkolainen, & Syvalahti, 2000; 
Mosher, Vallone, and Menn, 1979). Carpenter et al. (1977) succinctly sums the NIMH-
funded research of the 1970s,  
There is no question that, once patients are placed on medication, they are less 
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vulnerable to relapse if maintained on neuroleptics. But what if these patients had 
never been treated with drugs to begin with?... We raise the possibility that 
antipsychotic medication may make some schizophrenic patients more vulnerable 
to future relapse than would be the case in the natural course of the illness (p. 19).  
Despite the clear-cut conclusions favoring the non-drug treatments of all three NIMH and 
replication studies, the NIMH has decidedly moved away from this type of research. 
These studies had virtually no impact on the dominant position of drugs in the treatment 
of schizophrenia – yesterday or today (Breggin, 1991; Jackson, 2005). These studies 
became even more irrelevant in the minds of mainstream biopsychiatric researchers and 
clinicians following the development of the newer atypical neuroleptics (in the 1990s) 
which biopsychiatry currently deems superior to the older typical neuroleptics. However, 
as will be seen below, the superiority of atypicals over typicals is a faulty assumption that 
has further contributed to the over-reliance of neuroleptics as the frontline treatment for 
schizophrenia sufferers. Prior to direct empirical comparison of the older and newer 
drugs, in the service of an honest appraisal of drug treatments for schizophrenia, further 
review of studies that include both older and newer neuroleptics is in order.  
Effectiveness Research Including Typical and Atypical Neuroleptics  
If typical and atypical neuroleptics truly have specific ‘antipsychotic’ effects then 
they should show superior effects compared to simple sedatives (e.g., benzodiazepines). 
Yet, all reviews of the relatively scant ‘neuroleptic versus sedative’ literature found no 
differences between the two treatments (Carpenter, 1999; Keck, 1989; Wolkowitz, 1991). 
Whitaker (2002) ironically summed the evidence, “Forty years after neuroleptics were 
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introduced, and still there was no convincing proof that the [neuroleptic] drugs were any 
better at knocking down psychosis than old-fashioned opium powder” (p. 200). In 
response to these unsettling results, Turns (1990) self-deprecatingly asks, “Has our 
clinical judgment about the efficacy of antipsychotics been a fixed, encapsulated, 
delusional perception…Are we back to square one in antipsychotic 
psychopharmacology?” (cited in Whitaker, 2002, p. 200).  
Healy and colleagues (2005) took advantage of an idiosyncratic demographic 
situation in North Wales to study the effectiveness of psychiatric medications. In the 
region under investigation the population has been stable for at least a 100-year period in 
terms of number of people, age, ethnic mix and rurality. The authors found that there has 
been a three-fold increase in the rate of detention into psychiatric services and a 15-fold 
increase in the rate of hospitalizations since the introduction of medications. Speaking 
directly to medication effectiveness, the periods of healthy functioning for psychotic 
disorders such as bipolar disorders have actually become shorter, indicating that people 
are sicker more rather than less of the time. Overall, mentally ill patients spend a greater 
amount of time in a hospital bed today then they did 50 or 100 years ago. That is, 
treatments are becoming increasingly ineffective, even relative to Victorian times.  
 Not unlike the results presented earlier (Chouinard et al., 1978; Chouinard & 
Jones, 1980; Matthews et al., 1978; Mosher et al., 1979; Muller & Seeman, 1978), 
Whitaker (2005) has pointed out that medications are partially responsible for ever-
greater cases of chronic schizophrenia. He reported multi-site MRI evidence that have 
shown a connection between neuroleptic drug usage and enlargement of the basal ganglia 
which has been linked to greater severity of both positive and negative symptoms (e.g., 
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Gur et al., 1998). Whitaker (2005) concluded, “In other words, [research has] found that 
over the long term, the drugs cause changes in the brain associated with a worsening of 
the very symptoms the drugs are supposed to alleviate” (p. 8). 
Right up until the advent of the newer and more expensive atypical neuroleptics 
the drug industry and mainstream biopsychiatry actively promoted the effectiveness and 
safety of the original typical neuroleptics. Upon the advent of the atypicals, one finds 
greater discussion of the danger and marginal effectiveness of the typical neuroleptics 
once deemed ‘miracle cures’. Some believe that this honesty is better explained by the 
need for the drug-industry to promote and sell its more expensive atypicals now that the 
older drugs have lost their patents and thus profitability (Breggin, 1991; Whitaker, 2002). 
Within psychiatry and psychology, it is a widespread belief that the atypicals are 
clinically superior and safer than their predecessors. As will be shown, this belief is 
predicated upon information stemming from randomized controlled trials (RCT) mainly 
undertaken by drug companies during the FDA approval process. However, there are 
significant methodological flaws inherent in these trials, as well as a good deal of non-
drug company research refuting the superior effectiveness and safety of the atypicals. To 
this topic I now turn.  
Atypical Neuroleptics versus Typical Neuroleptics 
  There is little sound scientific evidence indicating the superior safety and 
effectiveness of the newer, atypical neuroleptic medications (Stip, 2002). Why then do 
the newer atypicals hold a 90% market share in the United States? The potential answer 
to this question may be that “physicians have come to rely increasingly upon information 
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from published sources (e.g., clinical drug trials) rather than from direct observation” or 
non-drug industry supported research (Jackson, 2005, p. 7) As the main data source for 
psychiatrists, it is imperative to understand the contemporary FDA drug trial research 
design (i.e., the Randomized Controlled Trials) employed by pharmaceutical companies 
that brings psychiatric drugs to the marketplace and justifies their widespread use for the 
treatment of schizophrenia.    
How a Psychiatric Drug Comes to the Marketplace 
 In 1962 the U.S. Congress empowered the FDA with the responsibility of 
assessing the therapeutic efficacy and safety of medications for inclusion in the 
marketplace. Because psychiatrists and other medical professionals rely almost entirely 
on the data generated in these drug trials for informing treatment, it is essential to 
understand the methodology of this process. Further, it is important to keep in mind that 
the RCT is also the preferred design for the subsequent, post-FDA approval process 
studies also generally sponsored by pharmaceutical companies. Thus, the following 
critique is generalizable to the vast majority of pre- and post-approval drug efficacy 
studies (Hegarty, Baldessarini, Tohen, Waternaux, & Oepen, 1994; Jackson, 2005; 
Thornley & Adams, 1998).   
 The FDA drug development process is divided into four phases. Phase I, or the 
‘Pre-Clinical Investigations’, involve the study of a drug’s effects on animals, cell 
cultures, and tissue samples. This phase aids in the determination of metabolic pathways, 
possible mechanisms of action, and toxicity. 
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 In Phases II-IV, the ‘Pre-Marketing Clinical Investigations’, human subjects are 
brought into the process. Phase II typically includes 100 healthy volunteers, with the 
intention of determining any adverse effects and general drug metabolism processes not 
detected in non-human species. This phase is essential for the development of a safe dose 
range without significant negative side effects. 
 Phase III includes between 100-300 individuals suffering from the illness the drug 
is meant to treat. The goal of Phase III is to fine tune dose range and nascent ideas 
regarding the drug’s efficacy for use with actual patients.  
 Phase IV studies are the last investigations required before receiving FDA 
approval. These studies are randomized, controlled, double-blinded trials consisting of 
approximately 1000 participants and commonly known as Randomized Controlled Trials, 
or RCT’s. RCT’s are short-term (4-8 weeks) and involve the testing of the proposed drug 
against other biological treatments and placebo (usually sugar pills). Upon completion of 
Phase IV, the pharmaceutical company files a ‘New Drug Application’ with the FDA 
outlining the results of the four phases. 
 The FDA looks for efficacy in at least two similar and well-monitored Phase IV 
trials. Efficacy is defined as “a statistically significant, therapeutic effect in the absence 
of unacceptable toxicities” (Hall, 2003, cited in Jackson, 2005, p. 9). Effect in this case is 
defined by comparing untreated (i.e., placebo) with drug-treated subjects, therefore there 
is no requirement that the proposed drug exhibit statistical superiority to other treatments 
such as psychotherapy. The FDA’s standard for psychiatric drug approval is “far more 
ambiguous than may be commonly assumed” (Jackson, 2005, p. 9). This ambiguity is not 
speculation, rather, it is a fact acknowledged by the FDA,  
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 The evidence adduced in the sponsor’s short term studies, although it 
unquestionably provides compelling proof in principle of (the drug’s) acute 
action, it does not provide a useful quantitative estimate of how effective the drug 
actually will be in the population for whom it is likely to be prescribed upon   
marketing (Leber, 1996, cited in Jackson, 2005, p. 10).  
The RCT method and design that provides “proof in principal” but not a “useful 
quantitative estimate” may be seriously flawed. Considering that these drug trials provide 
the evidence that guides schizophrenia treatment a more nuanced breakdown of the RCT 
is in order to clearly ascertain what we know and do not know about the safety and 
efficacy of antipsychotic medications.  
The RCT: A Scientifically and Clinically Flawed Approach 
 Published overviews regarding pharmaceutical company sponsored drug trials 
point out profound deficiencies in published and unpublished FDA research methods and 
designs (Antonuccio, Danton, & McClanahan, 2003; Breggin, 1991; Moncrieff, 2001; 
Safer, 2002; Whitaker, 2002). Again, it is essential to keep in mind that the RCT is the 
preferred design for subsequent, non-FDA studies as well. Thus the following critique is 
generalizable to the vast majority of drug efficacy studies used by psychiatrists when 
selecting treatments (Jackson, 2005; Thornley & Adams, 1998). Jackson (2005) provides 
the most recent integration of these critiques of the RCT and I will summarize her 
findings by highlighting the methodological flaws most relevant to the neuroleptic drugs 
currently used for the treatment of schizophrenia.   
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Flaw #1: Ecological Validity and Selection Bias. A main strategy in a drug study 
is to narrow the subjects as much as possible. Logically, this makes sense since the aim of 
a drug study is to determine efficacy of a certain drug with a certain illness. However, in 
the real world of clinical practice there is rarely such a thing as a ‘pure schizophrenic’. 
Yet, this is what the RCT design attempts to achieve. Common exclusions in an RCT are 
any or all of the following: age younger than 18 or older than 65; co-morbid physical or 
mental illness; pregnancy; severe distress (e.g., suicidal thoughts); inpatient status; and 
poor response to previous treatment. Rather than including these all-too-common 
variables as potentially informative covariates, they are generally excluded. The co-
morbidity exclusion is particularly problematic because contemporary research indicates 
that multiple Axis I problems are often intertwined with multiple Axis II personality 
processes greater than 50% of the time (Westen, Novotny, & Thompson-Brenner, 2004).    
  Flaw #2: Non-equivalent Dosing. In Phase IV of the FDA process, efficacy and 
safety are the target concerns. In these studies the newer atypical neuroleptics are 
compared to older typical neuroleptics. Equivalent dosing is defined as the administration 
of comparable doses of each drug, based on the well-defined chemical standards 
(Bezchlibynk-Butler & Jeffries, 2002). Non-equivalent dosing is the use of “super doses” 
(Jackson, 2005, p. 28) for one or the other medication in the trial. Since Phase IV 
concerns a patient simply staying on the drug for both a measure of efficacy and safety 
(i.e., no intolerable side effects resulting in discontinuation from drug exposure), dosing 
is an integral aspect of outcome. Obviously, it is scientifically and clinically unwise to 
use non-equivalent dosing since this will potentially lead to intolerable and/or dangerous 
side effects for a particular study group, and therefore disallow actual comparison of the 
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drugs themselves. Yet, this is the common practice for manufacturers seeking to gain 
approval for a new product. This strategy makes it more likely for researchers to 
conclude that the newer (i.e., more expensive product with a new patent) drug is safer and 
more effective. Of course, whatever symptom ratings scales are used will also reflect the 
newer drug’s superiority, because patients being overdosed on the older drug are in 
tremendous distress, both mentally and physiologically. Further, the hyper-sedative and 
other deleterious side effects of overdosing will artificially widen the gap between the 
groups in regard to negative symptoms (e.g., apathy, social isolation, flat affect). This is 
the origin of the regularly reported belief that compared to older typical agents the 
atypical antipsychotics are more effective for the treatment of negative symptoms.  
Phase IV of the atypical neuroleptic olanzapine approval process provides an 
illustrative example of non-equivalent dosing. In this study, olanzapine was compared to 
the typical neuroleptic haloperidol in the hope that it would provide compelling empirical 
proof to psychiatrists and other health care professionals that this new drug is safer and 
more effective and therefore should be turned to as a frontline treatment for 
schizophrenia. Table 2 illustrates the non-equivalent dosing strategy (Jackson, 2005, p. 
29). A comparable dose of haloperidol to olanzapine is 2 mg to 10 mg, respectively. 
Thus, in the high dose groups, haloperidol subjects received 4-6 times the olanzapine 
dose; in the medium groups, haloperidol subjects received 7-8 times the olanzapine dose; 
and in the low dose groups, haloperidol subjects received 8-20 times the olanzapine dose. 
Subsequent studies using either equivalent dosing (Rosenheck et al., 2004) or naturalistic 
design (Lieberman et al., 2005) have not found any of the atypicals to be superior in most 
respects when compared to the older medications.  
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 Flaw #3: Concomitant Medications. For patients with co-morbid ailments (e.g., 
diabetes), adjunctive medications are often being ingested during a drug trial. Of course, 
most if not all drugs cross the blood brain barrier and thus actively impact thinking, 
affect, and behavior (Breggin, 1991; Jackson, 2005). Although these potentially 
important covariates should undoubtedly be analyzed, they are ignored in RCT drug 
trials. Oddly, even when investigators prescribe a drug to ameliorate side effects of the 
study medication (e.g., drooling), this is not disclosed publicly nor is it analyzed 
empirically.  
 Flaw #4: Placebo Washout. Placebo washout is perhaps the most important factor 
leading to distorted information passed on to psychiatrists. Similar to non-equivalent 
dosing (Flaw #2), this practice is dangerous to the physiological and emotional well-
being of research participants. ‘Placebo washout’ is the 7-10 day period during which all 
participants abruptly discontinue previous medications immediately preceding the 
initiation of an RCT study. The intent is to ‘washout’ the brain of any chemicals so that 
prior drug use does not influence the study. The word ‘placebo’ is used because all 
participants are given an inert substance during this period so that subjects are not aware 
they have discontinued their medications. Upon initiation of the study the placebo group 
will of course continue to receive the inert pill or an older typical neuroleptic, while the 
experimental group will receive the drug under investigation. There are a variety of 
critical problems with this approach that result in significantly biased results that favor 
the experimental drug.  
 First, any patients who exhibit a positive response during the washout phase are 
removed from the study. As Jackson (2005) writes, 
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 …it is impossible to discount the presence of the same placebo effect…in the 
 subjects who go on to receive the active drug. As the placebo effect is necessarily 
a part of all healing rituals, it is illogically inconsistent to remove some subjects 
from a study, simply because they manifest this response too quickly (p. 31).   
Data provided by Faries and colleagues (2001) show that these positive responders 
continue to do well as the trial continues without active drugs. Consequently, removing 
these patients artificially inflates the differences between the experimental and control 
groups. Second, and more importantly, it is common that people experiencing abrupt, 
‘cold turkey’ discontinuation will experience substantial physiological and emotional 
fallout (Moncrieff, 2006). What is particularly strange about this practice is that abrupt 
withdrawal is widely documented within the mainstream psychiatric literature to be very 
dangerous (Addonizio, Susman, & Roth, 1987; Kornhuber & Weller, 1994). The most 
efficient, safest, and quickest way to moderate acute withdrawal symptoms is to provide a 
chemical intervention. Thus, most subjects in the placebo group experiencing acute 
withdrawal symptoms are at a significant disadvantage, since their bodies continue to 
adapt slowly to the sudden chemical changes. In contrast, the acute withdrawal symptoms 
of those in the experimental drug group are buffered more quickly with the 
administration of an active drug compound. This procedure translates into drug trials that 
are not measuring the effects of drugs or placebos on an underlying psychosis, but rather 
the treatment of acute withdrawal symptoms. Beyond this, it is empirically well-founded 
that the body cannot expunge the chemical properties of psychiatric agents within 7-10 
days (Breggin & Cohen, 1999; Hubbard, Ganes, & Midha, 1987). Rather, the withdrawal 
process takes weeks or months, and if attempted too quickly has permanent consequences 
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on brain tissue and neurologic pathways (Viguera, Baldessarini, Hegarty, van Kammen, 
& Tohen, 1997). These factors inculcate a unique bias into the antipsychotic drug trial 
literature and clinical practice.  
Flaw #5: Last Observation Carried Forward (LOCF) Analysis. LOCF is a 
statistical technique for reporting results of subjects who drop-out of a trial in which the 
researchers use the last recorded assessment for final outcome no matter the point at 
which they drop out (post-placebo washout). The assumption, of course, is that there 
would be no change if those participants had remained in the study. This often puts the 
placebo group at a profound disadvantage since many patients in this group drop out at 
their most distressed point of medication withdrawal immediately following the end of 
the placebo washout period. Of course, this practice artificially inflates the results of the 
experimental drug group.   
 Flaw #6: Unblinding. The double-blinded study design is intended to prevent 
patients, researchers, and clinicians (and anyone else connected to the study) from 
knowing group assignments. Due to the overt side effects of psychiatric medications, 
which are easily recognized by clinicians and researchers (and likely by patients), 
‘unblinding’ is common in drug trials and thus results may be strongly influenced by 
treatment expectations.  
Flaw #7: Omission of Data and Methodological Changes. In their review of 10 
drugs approved by the FDA between 1987 and 1997, Khan and colleagues (2000, 2001) 
found that drug companies omitted important and relevant data. The most serious 
omissions were the unreported data tracking suicide attempts and completed suicides for 
two antidepressants and two atypical antipsychotics. Additionally, during the olanzapine 
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approval process researchers changed the study from a 6-week study to a 4-week study 
due to too many subjects in the olanzapine group dropping out as a result of intolerable 
side effects (Jackson, 2005). The 6-week data was omitted from the final reports and only 
discovered by a request taking advantage of the congressional Freedom of Information 
Act. Recalculation of the 6-week data revealed results that are far less positive for 
olanzapine. Of course, omitted data and methodological changes make it difficult for 
subsequent researchers and clinicians to study and use the drug most effectively, safely, 
or not at all. The most recent (January 2007), but not isolated example of data omission, 
was seen in Eli Lilly’s recent $1.2 billion class-action settlement resulting from their 
failure to report results regarding the association between olanzapine, diabetes and 
morbid weight gain.  
Flaw #8: Redundant Publications, Suppression of Negative Results, and Ghost-
Writing. Recently, pharmaceutical company Eli Lilly has been found guilty of re-
packaging the same trial data in a series of overlapping papers in regard to the olanzapine 
approval process. Similarly, Glaxo Smith Kline recently re-packaged data in an attempt 
to exhibit the superiority of its product over a competitor’s drug. Besides this being a 
medical ethics violation, redundant publishing changes the findings of meta-analyses and 
thus evidenced-based medicine as we know it. 
In regard to negative results, there are two important distortions that impact the 
objectivity and validity of the drug trial literature. First, litigation has shown that drug 
companies have hidden negative results not only from the public, but from the FDA as 
well (Jackson, 2005). Second, many researchers who have conducted FDA trials are 
silenced by non-disclosure agreements, thus greatly tying their hands in regard to 
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reporting or whistle-blowing about dangerous medications. Antonuccio, Danton, and 
McClanahan (2003), Breggin (1991), and Ross and Pam (1995) all provide extensive 
documentation of these ethical violations. Third, ‘ghost writing’ is when an academic is 
paid to place his or her name on a paper or conference presentation to lend it authority. 
According to the deputy editor of the Journal of the American Medical Association, “This 
practice is well-known, scandalous, and outrageous. It is a perfect illustration of 
deceptive authorship practices for commercial reasons” (Larkin, 1999, cited in Jackson, 
2005, p. 39).    
The substantial flaws of controlled studies have recently been quantified in an 
extensive review of neuroleptic research, the results of which further erode confidence in 
the efficacy literature. In 1998, British researchers analyzed 2000 controlled efficacy 
trials conducted over the past 50 years (Thornley & Adams, 1998). The authors rated 
research methodologies according to the quality of randomization, blinding procedures, 
and the handling of patient attrition. Studies included consisted of trials of older and 
newer neuroleptics.  
In regard to overall quality of reporting, only 4% of the trials described how 
patients were assigned to experimental versus control groups; only 22% of the studies 
described blinding procedures; and only 42% of the trials described treatment 
withdrawals. The latter is highly significant because it speaks directly to the feasibility of 
treatment compliance, side-effects of the drugs, and physiological and psychological 
fallout resulting from placebo washout. Astoundingly, only 1% of the studies were 
considered of good quality.  
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Significantly, the duration of each trial was very brief. Whereas only 19% of the 
trials lasted for more than six months, more than half (54%) lasted six weeks or less. 
Considering the complex nature of schizophrenia and the amount of time it generally 
takes for people to show improvement (e.g., WHO studies), short trials are extremely 
non-representative of real-world treatment and clinical course. Furthermore, for a drug to 
be approved by the FDA and to be considered useful in general, it has to be shown to be 
not only efficacious, but safe for human consumption. Most central to safety, the very 
brief length of these studies makes it nearly impossible for drug trial researchers and the 
FDA to fully assess the inevitable short-term, but specifically long-term safety of 
neuroleptic drugs. This is highly problematic because it is common psychiatric practice to 
use neuroleptics as ‘maintenance medications’. That is, based on the general 
biopsychiatric belief that schizophrenia is a degenerative, incurable, chronic brain 
disease, neuroleptics are used for many years. In this sense, the brief drug trials do not 
approach a realistic assessment of long-term physiological and emotional side-effects.  
In sum, Thornley and Adams (1998) conclude, “The consistently poor quality of 
reporting is likely to have resulted in an overoptimistic estimation of the effects of 
[neuroleptic] treatment” (p. 1184). In response, Jackson (2005) writes of the accumulated 
neuroleptic effectiveness evidence,  
When, on rare occasion, the results of long-term…studies have appeared, the 
research has consistently supported the view that antipsychotics do more to 
impede, rather than facilitate, the recovery and longevity of many patients... 
Moreover, the low quality of the clinical trials have pervaded the psychiatric 
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literature has contributed to a body of evidence…whose validity and clinical 
relevance remain contestable (p. 191).  
Even with the pro-drug biases inherent in the FDA and non-FDA trial methodologies, the 
performance of new (and old) neuroleptics has been generally unremarkable (Stip, 2002). 
Despite the serious methodological flaws of the typical RCT, I will discuss the most 
recent meta-analyses and other studies to more clearly illuminate the strengths and 
weaknesses of the newer, atypical neuroleptics.  
Chakos and colleagues (2001) investigated the comparative utility of the atypicals 
in a twelve-study meta-analysis of treatment-refractory schizophrenia and concluded, 
“Efficacy data for other second-generation antipsychotics in the treatment of patients with 
refractory schizophrenia were inconclusive” (p. 518). Considering that studies included in 
the meta-analysis suffer from the pro-atypical neuroleptic biases just presented 
(‘superdoses’ of older drugs, placebo washout, LOCF, etc.) it is particularly informative 
that the results still did not favor the newer drugs. Furthermore, Chakos et al. (2001) 
identified a positive association between trial duration and drug efficacy, with longer 
study periods (i.e., a scenario more comparable to day-to-day psychiatric practice) 
eroding the few observed differences found between the older and newer drugs. All in all 
this meta-analysis refutes the superiority of the newer medications.  
Geddes and colleagues (2000) report results of a far larger meta-analysis (n = 
12,649) exploring the comparative value of the older and newer neuroleptics. Their 
results run contrary to the mainstream perception that atypicals are more efficacious and 
easier to tolerate in regard to side-effects. The authors conclude,  
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There is no clear evidence that atypical antipsychotics are more effective or are 
better tolerated than conventional antipsychotics. Conventional antipsychotics 
should usually be used in the initial treatment of an episode of schizophrenia 
unless the patient has previously not responded to these drugs or has unacceptable 
extrapyramidal side effects (p. 1371).  
These meta-analytic results have been replicated in prospective studies involving 
relatively chronic schizophrenic patients (Rosenheck et al., 2004), as well as patients 
earlier in their course of illness (Lieberman et al., 2003).  
 In a prospective, 12-month, multi-site drug trial comparing the atypical 
olanzapine with the typical haloperidol, Rosenheck and colleagues (2004) found no 
advantages for the newer drug in regard to treatment compliance (i.e., tolerability of side-
effects), psychotic symptoms, the development of extrapyramidal symptoms, 
improvement in interpersonal relationships, employment earnings, or overall quality of 
life. They did find that olanzapine reduced incidence of akathisia,5 but that these lower 
risks were offset by the significant weight gain, the development of diabetes, and 
treatment costs associated with olanzapine.  
 Lieberman et al. (2003) conducted a multi-site trial of olanzapine versus 
haloperidol in the treatment of recent onset schizophrenia. Despite significant 
methodological confounds favoring the atypical olanzapine, the authors still failed to 
detect any significant differences between the two medications. One outcome that was 
surprising was the high incidence of parkinsonism and akathisa among the olanzapine 
                                                 
5 Akathisia is a feeling of inner restlessness that results in a constant urge to move. While one cannot keep 
still when afflicted with akathisia, the movements are voluntary. This is distinct from the involuntary 
movements associated with tardive dyskinesia. These and other side-effects associated with exposure to 
neuroleptics will discussed in greater detail below.  
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participants. This was an unexpected finding because the newer drugs are supposed to be 
less dangerous in regard to extrapyramidal side effects.     
Perhaps in response to the many flaws of the RCT efficacy trials, the National 
Institutes of Mental Health (NIMH) is currently funding the largest-to-date, multi-site 
drug study to determine the effectiveness of atypical versus typical neuroleptics in 
naturalistic settings (e.g., community clinics). The naturalistic, effectiveness design will 
allow for longer periods of observation, less exclusion criteria, and will be far more 
generalizable to day-to-day practice compared to the RCT efficacy trials (for a discussion 
of the difference between effectiveness versus efficacy in treatment outcome research see 
Hilsenroth, Ackerman, Blagys, Baity, & Mooney, 2003). Also, the un-ignorable side 
effects observed by real-world practitioners belies the supposed safety of these drugs as 
reported in very brief drug trials and has further motivated a more ecologically valid, 
effectiveness trial. This ongoing study is known as the Clinical Antipsychotics Trial of 
Intervention Effectiveness (CATIE).  
CATIE: The Largest Naturalistic Study of Neuroleptics to Date 
 Lieberman and colleagues (2005) report the results of Phase I of CATIE that 
examined the comparative effectiveness of atypical versus typical antipsychotic 
medications. Their findings further refute the widely asserted proclamations that atypicals 
are actually more effective and have fewer side effects compared to older drugs.  
Lieberman et al. (2005) report no significant differences in the effectiveness of 
typical versus atypical drugs (n = 1432). As a measure of outcome they used early 
discontinuation due to intolerable side effects (the maximum length of Phase I was set at 
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18 months). It is important to not overlook the assumptions inherent in using early 
discontinuation as an outcome measure. Inherently, this assumes that simply staying on a 
medication indicates positive outcome, rather than measuring subjective or other 
clinically-observed change variables. Nonetheless, early discontinuation due to side 
effects does illuminate, at least partially, the feasibility of older and newer neuroleptics. 
The authors report mean early discontinuation rates across all drugs was an astoundingly 
high 74%. That is, only one in four participants was able to tolerate the drug for the 
entirety of the study period. The older drug, perphenazine, was not outperformed by any 
of the newer, far more expensive atypicals used with the greatest frequency in current 
clinical practice. The authors acknowledge that there is nothing unique about this finding 
because it is actually “consistent with…previously observed” outcomes found in smaller 
trials (pp. 1217-8). They conclude that the use of typical and atypical drugs exhibit 
“substantial limitations” (p. 1218). Yet, the authors do not offer any alternative other than 
to inform “patients, families, and policymakers [to] evaluate the trade-offs between 
efficacy and side-effects” (p. 1222). This recommendation is made despite the admission 
that, “The results of [this and other] studies of the effects of treatment on cognitive 
impairments and mood symptoms have been inconclusive…and incompletely explored” 
(Lieberman, 2005, p 1210).  
The authors of this paper fail to recommend that alternative approaches should be 
considered, despite available evidence indicating the safety and effectiveness of 
psychotherapeutic interventions (discussed below). Further, the fact that Lieberman et al. 
(2005) make conclusive remarks regarding the effectiveness of drugs based on 
approximately 25% of the subjects who managed to not drop-out speaks to their seeming 
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unwillingness to consider the overall danger and ineffectiveness of these treatments. 
After all, if three of four people stopped taking penicillin due to its intolerable side effects 
during WWII would the U.S. government have considered this an effective treatment for 
battle wounds, especially if viable alternatives were available? Such a scenario would be 
highly unlikely. Yet, when it comes to the neuroleptic treatment of schizophrenia, this 
level of ineffectiveness and physiological and emotional intolerableness is not merely 
acceptable, but deemed preferable.  
In conclusion, Gabbard and Freedman (2006) refer to Harvard social psychiatrist 
Leon Eisenberg’s cautionary comments on biopsychiatry’s neurobiological reductionism 
and concordant mandate for a medication-only approach in our field. They note,  
These directions recall Leon Eisenberg’s prediction that when the 
ultimate neurobiological treatment for schizophrenia is someday devised 
and everyone is marveling over the results on the computer monitor, there 
may be only one psychiatrist left who will remember to ask the patient, 
‘How do you feel’ (p. 183). 
Review of the most common side-effects of neruoleptic treatment is in order to further 
assess the effectiveness and safety of neuroleptic medications.  
Side-Effects of Neuroleptic Medications 
 The neuroleptic toxicity literature is rapidly growing as the dangerous short- and 
long-term side-effects of these chemical agents become increasingly clear to 
psychiatrists, consumers, their loved ones, as well as concerned patients’ rights 
advocates. While this review is not intended to be exhaustive, it will provide an 
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illustrative sampling of the most prevalent hazards associated with neuroleptic use. The 
interested reader would be well-served to read Jackson (2005) as well as Owens (1999) 
for more detailed accounts.   
 The most commonly recognized side-effects of neuroleptic use are known as 
‘extrapyramidal side-effects’ (EPS). EPS are the various movement disorders suffered as 
a result of ingesting neuroleptic dopamine antagonists. The best known EPS is tardive 
dyskinesia (TD) which results in involuntary, irregular muscle movements usually, but 
not limited to the facial region. For example, the patient may have facial tics, roll the 
tongue, lick the lips, and/or have trembling hands. Although TD might be managed or 
minimized by reducing the medication dosage or by changing type of medication, the 
symptoms may persist for long periods and often permanently, even after neuroleptics are 
decreased or even discontinued (Breggin, 1991, 1997; Jackson, 2005).  
Some forms of TD involve damage to the respiratory system which results in 
hyperventilation, abnormal vocalizations such as grunting, and violent chest contractions 
that can result in rib fractures (Hayashi, Nishikawa, Koga, Uchida & Yamawaki, 1996; 
Leung, Chung, Kam, & Wat, 2000). TD has regularly been empirically associated with an 
exacerbation of crippling negative symptoms such as social isolation and anhedonia 
(Waddington & Youssef, 1986), as well as positive symptoms (Miller et al., 2005).  
Other common EPS include acute dystonia which is an abnormal drug-induced 
state of either excessive or inadequate muscle tone. There are many forms of dystonia 
disorders which cause involuntary movements and prolonged muscle contraction 
resulting in twisting body motions, tremor, and abnormal posture, all of which are very 
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painful for the sufferer. These movements may involve the entire body or only an isolated 
area (Jackson, 2005). 
Many patients develop symptoms that mimic those of people suffering from 
Parkinson´s disease (Breggin, 1991). The symptoms include tremors, rigidity, temporary 
paralysis, reduced facial expression, shuffling gait and extreme slowness of movement. 
These symptoms usually appears in the first few days and weeks of neuroleptic 
medication administration. 
Akathisia is a serious condition associated with the use of neuroleptic medications 
and characterized by an internal sense of extreme agitation and motor restlessness 
(Jackson, 2005). Patients often describe their experience as being defined by an absolute 
inability to resist the urge to move. The most widely observed form of akathisia involves 
pacing and an inability to sit still. This side effect is often very distressing to the patient 
and reduces his or her ability to perform every day tasks. This bizarre consequence of 
neuroleptics also invites odd stares and exacerbates an already significant level of social 
alienation.   
A potentially fatal side-effect of neuroleptic treatment is known as neuroleptic 
malignant syndrome (NMS; Jackson, 2005). NMS includes diffuse muscle rigidity, 
tremor, high fever, labile blood pressure, cognitive dysfunction, and autonomic 
disturbances. This condition can be sudden and often occurs early in the course of 
treatment. However, it has also been documented to occur after months and years of 
neuroleptic medication use.  
 In a recent review of the EPS literature, Glazer (2000) summed evidence from a 
cohort of 362 patients. Glazer found a positive relationship between cumulative duration 
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of neuroleptic treatment and EPS, thereby replicating previous reviews (e.g., Glazer, 
1992). It is widely assumed that EPS develops only after years of exposure to 
neuroleptics. However, Jeste and colleagues (1999) found that older patients are 
particularly susceptible to EPS, even when exposed to neuroleptics for a short period 
(e.g., within the first month of treatment). In regard to patients within a more 
representative age range (mean age of 28), Oosthuizen and colleagues (2003) have shown 
that even minimal exposure to neuroleptic treatment can cause substantial EPS in a 
relatively short period of time (i.e., at one year follow-up).   
 The emergence of the newer atypical neuroleptics has been accompanied by an 
assumption that these newer drugs reduce the risks of EPS. The summed research 
suggests that approximately 50-90% of all patients treated with the older typical 
neuroleptics will experience some form of EPS. In contrast it has been estimated that as 
many as 20-50% of atypical recipients will suffer the consequences of drug-induced EPS 
(Malla et al., 2004). Two recent studies report no significant differences between the 
newer and older drugs in regard to neurotoxicity (Bonelli et al., 2005; de Leon, in press). 
Therefore, while the reduced risks are questionable, it is clear is that the incidence rates 
of EPS associated with the newer atypical drugs are still quite substantial.  
 If there are reduced risks of EPS enjoyed by the atypical neuroleptics, they are 
potentially outweighed by the unique tendency of the atypicals to contribute to obesity 
(Meyer, 2001), cardiovascular disease (e.g., Osby et al., 2000), diabetes (e.g., Dixon et 
al., 2000) and dysmetabolic syndrome (e.g., McEvoy et al., 2005). The latter, 
dysmetabolic syndrome, is defined by clinical features that include obesity, abnormal 
density of lipoproteins, elevated fasting triglycerides, hypertension, and impaired fasting 
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glucose or overt diabetes mellitus. While diabetes represents a disease entity with a high 
risk for cardiovascular disease, dysmetabolic syndrome’s cluster of physiological 
symptoms is deemed an even more dangerous precipitant to heart trouble.  
McEvoy et al. (2005) found that compared to a matched normative sample, male 
and female schizophrenics exposed to atypical antipsychotics are respectively 138% and 
251% more likely to have dysmetabolic syndrome. A staggering 41% of all schizophrenia 
patients in this sample developed dysmetabolic syndrome. In a 10-year longitudinal 
study, Henderson and colleagues (2005) report similar results specifically related to the 
atypical drug clozapine. In addition to these dymetabolic syndrome studies illuminating 
the greater risks neurolepticized schizophrenics face in regard to the gradual 
development of heart disease, Sabine and colleagues (2004) report neuroleptic use is also 
associated with sudden cardiac death, even at low doses.  
 In regard to sexual dysfunction, typical and atypical drugs have been shown to 
produce prolactin imbalances regularly linked to infertility (e.g., Alexiadis, Whitehorn, 
Woodley, & Kopala, 2002). Older and newer neuroleptics have also been linked to 
decreased libido, erectile and ejaculatory dysfunction, gynecomia, and amenorrhea (e.g., 
Bobes et al., 2003).  
 Recent studies have replicated results that have found a positive association 
between neuroleptic use and mortality. For example, Healy and colleagues (2006) present 
data indicating the greater risks of suicide faced by schizophrenics treated with typical 
and atypical neuroleptics compared to non-medicated schizophrenics. The investigators 
compared detailed asylum records of psychotic admissions in Victorian North Wales 
(1875-1924), within the same geographic locale to similar records kept between 1994 and 
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1998. The authors found a startling result: patients treated with the latest antipsychotic 
drugs had a 20-fold increased risk of suicide compared to those treated without drugs in 
the Victorian era. Data from the British Medicines Healthcare Regulatory Agency 
(Alliance for Human Research Protection, 2006) confirm that antipsychotics (as well as 
antidepressants) are implicated in the greatest number of suicides and suicide attempts in 
the United Kingdom. These data further suggest the decline in mental health care 
associated with medication-only treatments.  
Joukamaa and his Finnish colleagues (2006) also found an association between 
typical neuroleptic use and mortality in schizophrenia in their 17-year longitudinal study. 
They found that schizophrenic individuals in general have a 1.29-to-1 relative risk of 
mortality compared to normal controls. Thus, just having schizophrenia puts you at risk 
above the general population. This is neither surprising nor unexpected. However, 
following adjustment for age, gender, somatic diseases and other potential risk factors for 
premature death, the authors found that “[t]he number of neuroleptics used at the time of 
the baseline survey showed a graded relation to mortality” (p. 122). Specifically, the 
relative risks for people with schizophrenia taking one, two, or three or more neuroleptics 
at baseline were (95% CI) 2.97, 3.21, and 6.83, respectively. The association remained 
stable throughout the 17-year follow-up period. According to these results, neuroleptics 
may be more than ineffective, they may be dangerous. These findings replicate previous 
studies that similarly found an association between polypharmacy and increased mortality 
rates with both typical and atypical neuroleptics (Bralet, Yon, Loas, & Noisette, 2000; 
Morgan et al., 2003; Osby, Correia, Ekbom, & Sparen, 2000; Reilly, Ayis, Ferrier, Jones, 
& Thomas, 2002; Wallington, Youssef, & Kinsella, 1998). 
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  One of the predominant features of schizophrenia is disorganized thinking. As 
such, medications meant to treat schizophrenia should help rather than harm cognition. 
However, this is not always the case. Kasper and Resinger (2003) found that neuroleptics 
actually contribute to cognitive impairments rather than ameliorate them. Minzenburg 
and colleagues (2004) found that neuroleptic medications negatively impacted visual 
attention, general intelligence, and short-term declarative memory after controlling for 
psychopathology and cognitive ability. A variety of studies document the relationship 
between neuroleptic use and executive functioning and working memory (Gilbertson & 
van Kammen, 1997; Mehta, Manes, Magnolfi, Sahakian, & Robbins, 2004; Papageorgiou 
et al., 2003; Sweeney, Keilp, Haas, Hill, & Weiden, 1991; Vitiello et al., 1997), sustained 
attention and arousal (Cassens, Inglis, Appelbaum, & Gutheil, 1990; King, 1994), 
reaction times (Ridout & Hindmarch, 2003), information processing (Brebion, Amador, 
Smith, & Gorman, 1998), fine motor coordination (Cleghorn, Kaplan, Szechtman, 
Szechtman, & Brown, 1990), temporal processing (Rammsayer, 1997), latent inhibition 
(McCartan et al., 2001), and procedural learning (Scherer et al., 2004).  
Clearly, the physiological and cognitive side-effects of neuroleptic treatment are 
serious consequences needing to be factored into our general treatment approach to 
schizophrenia, along with the fact that there is no empirical evidence documenting any 
deleterious side-effects of psychotherapeutic interventions. Therefore, it is not 
unreasonable to suggest that psychotherapy need only fare equal to, or of course better 
than, neuroleptics for treating schizophrenia since the neuroleptic side-effects place the 
medications at a serious clinical disadvantage. In this vein, I will now explore the 
empirical effectiveness of psychodynamic psychotherapy.  
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Section IV: The Effectiveness of Psychodynamic Psychotherapy of Schizophrenia 
The “tragedy” of schizophrenia in our modern mental health care system is that 
we know of treatments that work – namely, psychodynamic psychotherapy - but very 
rarely offer adequate training or resources for this approach (Karon, 2003, p. 89). 
Although there are a number of psychodynamic perspectives that inform the treatment of 
schizophrenia, it is possible to extract a number of common threads that bind these 
approaches together. Some of the more prominent psychodynamic clinicians, theorists, 
and researchers contributing to these core ideas include Arieti (1974), Boyer, Giovacchini 
& Hoedemaker (1967), Fromm-Reichmann (1950), Karon & Vandenbos (1981), Searles 
(1960, 1965), Will (1968) and Sullivan (1953, 1962).  
To start, what psychodynamic psychotherapy of schizophrenia is not is classically 
psychoanalytic. That is, clinicians working with this severe population do not have 
patients lying on a couch, facing away from them, or promote regression via a general 
stance of clinical abstinence and neutrality; nor do therapists aggressively provide genetic 
or defense interpretations as would be expected in the treatment of a neurotic-level 
patient. This is an important point because it is generally assumed by psychiatrists and 
non-psychodynamic therapists that there have been no amendments to the original 
Freudian approaches/tenets in regard to schizophrenia. This misunderstanding has been 
most recently repeated in the PORT study’s out-of-hand rejection of the use of 
psychodynamic therapies based on the faulty notion that such treatments promote 
“regression and psychotic transference” (Lehman & Steinwachs, 1998, p. 8). Since the 
PORT was convened to review the clinical literature to create treatment 
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recommendations for practicing psychiatrists and psychologists this misperception is 
extremely significant. Fortunately, Ver Eecke (2003), Gottdiener and Haslam (2003), and 
Silver (2003) each provide a clear, theoretical and empirical-based critique of the 
mistaken conclusions of the PORT. 
The contemporary psychodynamic approach to schizophrenia is more accurately 
depicted to include the following core tenets: 
1) A patient has a narrative that is highly relevant to his or her 
psychological suffering. It is imperative to consider the role of the 
patient’s early environment/experiences as a partial contributor to the 
patient’s interpersonal difficulties, preferred defensive style, and overall 
symptomatic distress. Another way to express this idea is to consider a 
patient’s life events, both positive and negative, as contributors to each 
patient’s idiosyncratic (and often psychotic) attempts to adapt to the 
complexities of our social, vocational, and interpersonal world. 
2) The therapist should listen seriously and respectfully to each 
individual’s subjective affective and cognitive experience, no matter 
how seemingly bizarre or ‘irrational’.  
3) The therapist should attempt to understand the symptoms of 
schizophrenia as symbolic communications of unresolved and very 
distressing interpersonal dilemma(s) stemming from a core confusion in 
which “one cannot maintain a border between where [s/]he ends and 
where objects [i.e., other people] and their internalized representations 
start” (Volkan, 1995, p. 27). These object relations, that is, one’s 
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internal representations of self/other and external patterns of relating, 
are believed to be exacerbated by, and a product of, an internal world 
full of split (i.e., conflicting affect states held apart from each other) or 
even fragmented self- and other-images often saturated with powerful, 
un-neutralized affect states.  
4) The internal situation referred to in #3 results in a fairly constant panic-
level anxiety that leaves the schizophrenic patient feeling as if he or she 
is in continuous existential danger. This internal dread is often 
externalized and obscurely communicated in delusional and 
hallucinatory symptoms often of a paranoid nature. Psychodynamic 
theory understands these psychotic symptoms, as well as acute 
withdrawal from social relations, as defenses (or, poorly adaptive 
solutions) used to protect the schizophrenic patient from powerful 
internal affect states that are psychotically distorted as external threats.   
5) Due to its understanding of the intensity of affects underlying defenses 
in schizophrenia, psychodynamic therapy is designed to assist patients 
develop more adaptive defenses/solutions, as well as conscious insight 
to help patients more realistically express their internal experiences, and 
“convert raw anxiety into sublimated cohesive” self understanding 
(Silver, Karon, & Koehler, in press, cited in Silver, 2003, p. 330). 
6) Karon and Vandenbos (1981) outline three essential functions of the in-
the-room relationship. First, the therapist-patient relationship should 
provide sufficient protection and gratification to overcome the 
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conscious resistance the patient has to engaging the therapeutic process. 
Due to a history of very troubled interpersonal relationships, the 
therapist needs to present him- or herself as “a strong, protective, more 
gratifying figure than [s/]he would be in the therapy of [healthier, non-
psychotic] patients” (p. 145). Second, that which transpires verbally and 
non-verbally in the room between the schizophrenic patient and 
therapist is highly relevant to his or her troubling patterns of 
internal/external interpersonal experiences. Thus, within the therapeutic 
relationship a schizophrenic patient, similar to any other patient, 
“relives feelings and experiences from the past [i.e., transference]…thus 
providing an enormous source of information as to what [the patient’s] 
life history and problems were truly like” (p. 146). This type of 
information is intended to allow for slow resolution/understanding of a 
particular patient’s core anxiety laden conflicts. Third, the therapist’s 
sustained curiosity, warmth, desire to help, and refusal to accept 
therapeutic failure should function as a reliable model for identification. 
Identifying with the therapist in this way is intended to modify the 
unusually harsh super-ego’s common to schizophrenia patients.  
7) Psychodynamic theory holds that under enough stress, especially in the 
context of a limited support system, anyone is susceptible to degrees of 
psychoticism.  
8) Psychodynamic approaches assert that schizophrenia is not solely a 
‘chemical imbalance’ nor is it a degenerative brain disease. Rather, 
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schizophrenia is a complex and extreme biopsychosocial reaction to 
troubling real-world experiences. 
9) Therapists working with schizophrenic patients must have a high 
tolerance for confusion and frustration and be free of the need to derive 
narcissistic gratification from the patient’s therapeutic efforts and/or 
success (Bachmann, Resch, & Mundt, 2003).  
Beyond psychodynamic psychotherapy there is growing evidence that other modalities, 
such as cognitive-behavioral treatment (e.g., Turkington et al., 2006), residential-based 
milieu treatment (e.g., Mosher, Vallone, & Menn, 1995), social learning treatment (e.g., 
Paul & Lentz, 1977), Open Dialogue treatment (Seikkula, Alakare, & Aaltonen, 2000; 
Seikkula et al., 2003) and family treatment (e.g., Schindler, 1980) are effective 
alternatives adjunctive to or independent of medication treatment. For the sake of brevity 
and because it reflects the empirical component of this dissertation project, this review 
will focus solely on the empirical literature exploring psychodynamic and 
psychodynamically-informed treatments. 
Research Investigating the Psychodynamic Psychotherapy of Schizophrenia  
 Due largely to the drug-bias in the modern mental healthcare system there have 
been very few randomized studies that explore psychotherapy without adjunctive 
medication (Jackson, 2005). However, of the four that do exist the overall results indicate 
the promise of psychodynamic work with schizophrenia, despite significant limitations 
impacting two of these studies in particular (for a review see Karon, 1989).    
 69
 Carl Rogers and colleagues (1967) performed a randomized clinical trial 
comparing person-centered therapy to a neuroleptic-only treatment approach. Although 
person-centered therapy is not psychodynamic, many of its core tenets are deeply 
influenced by and comparable to a contemporary psychodynamic approach – especially 
in regard to the treatment of the more severely ill. For example, Rogers’ approach, 
similar to any psychodynamic approach, focuses a great deal of attention on the in-the-
room relationship. Rogers et al. write, “…the most essential ingredient for change will be 
found in the attitudinal qualities of the person-to-person relationship (p. 92).  
 In this study, there were 16 early phase schizophrenics and 16 chronic 
schizophrenics. After matched pairing, the schizophrenic patients were randomly 
assigned to each of two treatment groups: psychotherapy-only and neuroleptic-only. 
Therapy was given twice a week for up to 2.5 years. Outcome was assessed by blind 
reviewers, the therapists and the patients themselves. All significant findings favored the 
psychotherapy group including improved interpersonal relationships, enhanced capacity 
to openly experience and express their emotions, and better ability to “face their 
environment and themselves” (cited in Irwin, 2004b, p. 100). Importantly, the 
psychotherapy group spent an average of 112 fewer days in the hospital following the end 
of the psychotherapy phase of the study. Therapeutic alliance defined by genuineness, 
empathic attunement, and affective congruence was positively related to outcome. 
Psychotherapy patients who did not experience as positive a therapeutic relationship did 
not fare as well by the study’s end, suggesting the important mutative impact of the 
patient-doctor alliance. Limitations of the study included small sample size and lack of a 
placebo group. Strengths included treatment fidelity which was measured and rigorously 
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monitored. That is, the research and clinical supervisors of this study were committed to 
the psychotherapy component of the study.  
 May and colleagues (1976, 1981) randomized 228 early episode individuals 
suffering with schizophrenia to one of five treatments: psychodynamic psychotherapy 
without medication, psychodynamic psychotherapy with medication, medication-only, 
ECT, or milieu therapy. All groups received milieu therapy and therefore the milieu 
group served as the control cohort. Psychotherapy was provided for two years at two 
times per week. Outcome measures included number of days hospitalized, social 
competence, and global functioning derived from patient interviews, families, social 
workers and hospital records. After two years the only significant difference found was in 
number of hospital days, favoring the medication-only group; after 3, 4, and 5 years there 
were no significant differences found. Karon (1989) extensively critiques the quality of 
psychotherapy provided in this study based on the supervisors’ reported lack of 
experience and negative expectations of the utility of psychotherapy for schizophrenia. 
Even with these limitations handicapping the psychotherapy patients, the medication-only 
individuals, in general, did not outperform them. Other limitations also include the lack 
of a placebo group and lack of blinding for most assessments (which likely deleteriously 
impacted the psychotherapy group due to negative treatment expectations held by the 
research team).  
 Grinspoon and colleagues (1972) randomized 41 people diagnosed with chronic 
schizophrenia into three groups: 21 remained in the hospital where they continued 
neuroleptics; 10 were given placebo for 13 weeks and then restarted on neuroleptics; and 
10 were given placebo for 13 weeks and then provided with psychodynamic 
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psychotherapy. At five years two trends (p = .07) favoring the psychotherapy patients 
were detected, including decreases in psychotic symptoms and better capacity to adapt to 
life outside of the hospital. Perhaps due to their inability to shed their drug bias the 
researchers referred to the improvements in the psychotherapy group as “an artifact” (p. 
1126). Karon and Vandenbos (1981), Karon (1989), as well as Irwin (2004b) outline 
substantial limitations of this study. First, over half of the psychotherapy patients had 
previously received at least one round of ECT, insulin shock, or both. As Karon and 
Vandenbos write, “Psychotherapists experienced with treating schizophrenic patients 
have doubts about attempting psychotherapy with patients who have had ECT or insulin 
comas [due to the organic damage resulting from such intrusive treatments]…No serious 
study of psychotherapy would include such patients…” (p. 380). Beyond this, the 
therapists used in this study had very little experience with treating schizophrenia or 
patients from the cultural and socioeconomic group of those included in the project. In 
fact, retrospectively, most of the therapists in this study explicitly expressed doubt about 
the quality of the psychotherapy provided in this study (see Karon, 1989). Lastly, the 
drug washout time of 13 weeks is not considered adequate (Breggin & Cohen, 1999), 
thereby making this a study of drug withdrawal as much as anything else. Despite these 
limitations negatively impacting the psychotherapy patients, these individual fared 
relatively well with the aid of psychodynamic psychotherapy.  
 Karon and Vandenbos (1981) completed the last randomized trial of 
psychodynamic psychotherapy of schizophrenia of the 20th century in the late 1960’s. It 
is this study from which the current project’s data are derived. As reported above, at the 
conclusion of their 20-month investigation the researchers found that patients receiving 
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psychotherapy significantly outperformed individuals receiving medication-only on three 
of four instruments assessing patients’ thought disorder, on a blindly rated clinical status 
interview, and days spent in the hospital due to mental dysfunction. On the fourth 
measure of thought disorder, differences between the psychotherapy and medication-only 
patients approached significance (p = .07). Individuals of the medication-only group did 
not fare better in any area assessed. More specific details of Karon and Vandenbos’ 
investigation will be explored in the ‘Methods’ section below.  
 Gottdiener & Haslam (2002) recently conducted the first comprehensive meta-
analytic review of individual psychotherapy of schizophrenia, including in their analysis 
between- and within-groups designs as well as psychotherapy designs with or without 
adjunctive medication. These important inclusions have been missing from past meta-
analyses investigating schizophrenia outcome research (Cormac, Jones, & Campbell, 
2002; Malmberg & Fenton, 2001; Mojtabai, Nicholson & Carpenter, 1998; Smith, Glass, 
& Miller, 1980). Gottdiener and Haslam examined studies exploring cognitive-
behavioral, psychodynamic, and non-psychodynamic supportive therapies. 
Gottdiener & Haslam (2002) report an overall corrected effect size of r = .36 
across the three treatments. Psychodynamic (r = .39) and cognitive-behavioral (r = .41) 
treatments with and without medications were found to be equally effective. Non-
psychodynamic supportive therapy exhibited a relatively smaller effect (r = .27; no 
significance test was conducted). Despite the PORT recommendations (Lehman & 
Steinwachs, 1998) and other empirically unsupported admonishments (e.g., Drake & 
Sederer, 1986) against the use of psychodynamic therapy, insight-oriented therapy fared 
quite well relative to other psychotherapy modalities.  
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As the entirety of this dissertation project has made clear until this point, there is a 
strong biopsychiatric belief that neuroleptics are the most effective form of treatment for 
schizophrenia. However, Gottdiener and Haslam (2002) report that use of medications 
did not impact effect sizes at all. That is, when medications were used with 
psychotherapy the effect size was identical to when medication was withheld (r = .31). Of 
course, the participants being treated without medications were free of the various side-
effects caused by these potent chemical agents. In sum, similar to the few randomized 
trials reported earlier, this meta-analysis provides additional evidence that 
psychodynamic psychotherapy is safe, effective, and without doubt worthy of additional 
empirical attention.  
In concluding this introduction, based on 1) the philosophically and empirically 
untenable degenerative and psychotoxicity assumptions; 2) significant flaws in the FDA 
approval process and the RCT design in general for use in schizophrenia research; 3) the 
empirically documented ineffectiveness of typical and atypical neuroleptic treatments; 4) 
severe side-effects of neuroleptic treatments; and 5) the effectiveness of psychodynamic 
psychotherapy, one is left seriously reconsidering the wisdom of a medication-only 
treatment approach in lieu of existing alternatives. I will now continue with the empirical 




Section V: Pre- to Post-Treatment Change in the Object Relations of Schizophrenic 
Patients 
As mentioned, the experimental design utilized in the original study conducted by 
Karon and Vandenbos (1981) called for the selection of schizophrenic patients to be 
assigned on the basis of a random number table to one of three treatments: 1) 
psychotherapy without medication (Psychotherapy-only, A); 2) psychotherapy with 
adjunctive medication (Mixed, B); and 3) routine hospital treatment consisting primarily 
of phenothiazines (i.e., typical neuroleptics; Medication-only, C). The adjunctive 
medication provided to individuals of the Mixed group (B) was discontinued after the 
first few weeks of the study. Overall, 36 patients were evenly distributed among the three 
treatment groups. The small number was necessary in order to be careful about gathering 
detailed and rigorous data throughout the 20-month study. The small numbers in the 
psychotherapy groups (A and B) also allowed for more efficient ‘quality control’ of 
psychotherapeutic treatment by experienced supervisors. This was particularly important 
because, as mentioned earlier, the quality of psychodynamic therapy provided in past 
randomized studies has been seriously called into question in regard to the quality of 
training the therapists had, the therapist’s specific experience with psychotic patients, and 
researcher bias (Karon, 1989). Due to incomplete data available for the Mixed group (B), 
this cohort has been removed from the current study. Although this is an unfortunate loss 
of potentially useful and interesting data, the primary and unique aspect of the experiment 
is the assessment of a completely non-medicated group. That is, while there are studies 
exploring mixed treatment approaches (see for a review Gottdiemer & Haslam, 2002), 
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there are as far as could be determined no published U.S.-based studies in the last 25 
years that utilized a fully non-medicated group.     
Clinical Participants  
All inpatient admissions to the Detroit Psychiatric Institute (DPI) were reviewed 
for possible inclusion in the project. Evaluation for selection was solely in terms of 
meeting the selection criteria discussed below. Selection was made by using the same 
criteria and research personnel throughout the entirety of the project. Patients were not 
selected by regular hospital staff or with an eye to whose patients they might become. 
The intent to obtain schizophrenic patients with no organic pathologic condition or 
previous hospitalizations required adequate case histories and thorough medical 
examinations before selection into the project. This process required two weeks for each 
case. Patients were not assigned to treatment groups until there were three patients who 
had completed preliminary medical and diagnostic examinations so that the ‘set’ could 
then be randomly assigned. If a patient was discharged before assessment was complete 
that patient was replaced as a potential project patient by another patient who met the 
requisite criteria and was still hospitalized.  
The admission rate to the DPI ward was approximately 5,000 patients per year 
throughout the 1960s (Karon & Vandenbos, 1981). Hence, in any given week a pool of 
about 100 potential research patients would be reviewed using the initial criteria. 
However, roughly two-thirds of these patients were discharged within two weeks, 
therefore precluding completion of the extensive medical and diagnostic assessment. As a 
result, the actual pool of potential research subjects was about 35 per week. Only one set 
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of three patients was selected in a given week. All the patients were selected within a 4-
month period. Any differences in patient characteristics reflect possible week-to-week 
fluctuation in admissions and therefore were well within the bounds to be expected from 
random variation.  
Patients utilizing services at DPI were primarily poor, inner-city African-
Americans. The initial selection process was to select acutely ill (i.e., not chronic) and 
clearly schizophrenic patients. Six criteria were mandatory for inclusion. The first and 
most important criterion was that the patient needed to be unquestionably schizophrenic. 
The diagnoses of patients in the study were made by two independent research personnel 
(clinical psychologists) with considerable experience in the treatment and diagnosis of 
schizophrenia, neither of whom was connected with treatment of the clinical patients. 
DSM-II criteria and medical screening for organic illnesses were utilized to guide the 
diagnostic process. Both experts had to agree with the schizophrenia diagnosis for the 
patient to be included. Further, the DPI Ward Chief as well as an independent psychiatric 
resident also had to concur with the diagnosis for the patient to be included in the project. 
Criteria two through six included: 2) onset of blatant psychotic symptoms within 3 
months prior to admission; 3) first admission; 4) no history of ECT or insulin shock 
treatment; 5) no organic brain damage; and 6) no history of alcoholism or drug addiction.  
Of particular relevance to this sample, Dunham (1965) found that the median time 
between onset of blatant psychotic symptoms and the first presentation to treatment was 
34.5 months for poor, inner-city African-Americans. Since these patients tended to be ill 
for some time prior to admission at DPI, criterion three (i.e., “first admission”) is 
misleading as these patients were more severely impaired and chronic compared to other 
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first admissions derived from less impoverished communities. Severity of illness was best 
observed on the pre-treatment scores on the Drasgow-Feldman Visual Verbal Test (VVT; 
Feldman & Drasgow, 1951) for which 29 of 35 patients scored at or below the norms for 
chronic schizophrenic individuals. Importantly, VVT normative data were drawn from 
schizophrenic patients hospitalized for 3 or more years. Thus, across groups, these poor, 
generally African-American patients exhibited a very severe level of chronicity atypical 
for first admission schizophrenics. Exacerbating the severity was that initial screening 
failed to reveal 11 previous hospitalizations (Psychotherapy-only = 4, Mixed = 2, 
Medication-only = 5). Patients and their families reasoned correctly that a previous 
hospitalization leads to worse treatment in general and therefore they actively concealed 
this information.   
Despite the attempt at careful medical screening, some medical problems were not 
accurately revealed during the initial screening process. Four dramatic instances 
occurred. Two catatonic patients died of embolisms. The first died before randomization 
had occurred and was therefore replaced without jeopardizing random assignment. The 
second patient (a female in the Psychotherapy group treated by a trainee) died following 
group assignment. She was therefore not replaced as such an assignment would not be 
purely random. A female patient being treated by the Psychotherapy group supervisor 
(Karon) was eventually diagnosed with multiple sclerosis despite being originally cleared 
by the neurology and internal medicine services. It was only after psychotherapy 
improved her thought disorder, reality testing and interpersonal distress that this patient’s 
remaining motor impairments (this patient had a gait all along) were properly understood 
as symptomatic of multiple sclerosis. Since the patient was indeed clearly schizophrenic 
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and the two sets of symptoms followed independent courses, this patient was included in 
the data. Karon and Vandenbos (1981) found that analyses were not significantly altered 
by exclusion of this patient and so she will remain in the proposed study as well.  
Another patient (a male in the Psychotherapy group treated by a trainee) initially 
denied a history of drug abuse. However, during the course of psychotherapy this 
patient’s verbalizations revealed a possible history of addiction. Subsequent collateral 
contacts with the patient’s girlfriend and family revealed that for many years he had taken 
seconal, Dexedrine, and nutmeg in daily irregularly large doses sufficient to produce 
brain damage. This patient was excluded from the data analyses in light of the 
inappropriate selection for the project. A third patient was excluded from the treatment 
because of grossly unprofessional staff interference described in detail in Karon and 
Vandenbos (1981). In sum, the Psychotherapy-only group lost three patients: one patient 
died from an embolism, one was excluded due to a previous addiction history, and a third 
was excluded because of gross staff interference. Therefore, the original analyses 
included nine subjects in the Psychotherapy-only group, and 12 in the Mixed and 
Medication-only groups (total n = 33). Thus, the proposed study utilizing only the pure 
groups will have a final n-size of 21 (Psychotherapy-only = 9; Medication-only = 12).  
Assignment of patients to experienced and inexperienced therapists was on a 
rotation basis. Psychotherapy supervisors did not select which patients with whom they 
would work. Psychotherapy supervisors were assigned two research patients previous to 
assignment of patients to trainees. These cases served as training cases and were viewed 
on closed-circuit TV and subsequently discussed.  
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Therapists 
 There was one experienced supervisor for each of the psychotherapy treatment 
groups. Each supervisor ultimately treated four patients. ‘Experienced’, as used in this 
study, means approximately 10 years of experience specifically treating schizophrenic 
patients (i.e., not merely doing psychotherapy but treating schizophrenic patients). Both 
supervisors also had lengthy experience working with poor, inner-city African-American 
patients. The psychology interns and psychiatric residents had three months to one year 
of general practicum or residency experience before the initiation of the project. In 
addition to supplemental texts designed to inform (though not manualize) treatment, the 
trainees watched via closed circuit TV the beginning of the treatment of two patients by 
their respective group supervisor before they began to work with their own patients. To 
facilitate training, trainees’ early sessions were viewed on closed circuit TV by the 
supervisor, as well as the other group trainees. In the latter phases of the study, 
conventional individual supervision sessions were held. Trainees were monetarily 
compensated throughout most of the study. At mid-project (approximately 12 months) 
payments were suspended due to an intra-professional rule change precluding students 
from accepting monetary compensation while matriculating. Trainees agreed to work for 
several months without pay until the project supervisors were able to reinstitute 
payments. It is possible that withheld payments may have affected motivation of trainee 
therapists and impaired the effectiveness of their performance during the period of 
withheld compensation. All project therapists were Caucasian, reflecting the ethnic 
composition of the hospital’s professional staff and of the clinical psychology and 
medical students. Minority students were unavailable in the programs in which the 
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trainees matriculated. Medical and psychology students were evenly distributed among 
the psychotherapy treatment groups to minimize professional jealousies as a 
contaminating factor.  
Explanation of Psychotherapeutic Treatment 
Because the Mixed group will not be investigated in this proposed study, only the 
technique and theory of the Psychotherapy-only group will be presented. The 
Psychotherapy-only group used psychodynamic psychotherapy without medication. The 
derivative of psychodynamic therapy utilized with these patients was largely influenced 
by Karon’s (1994; Karon & Vandenbos, 1981) interpretation of the theory and technique 
of Sullivan (1953, 1962) and Fromm-Reichmann (1950). Briefly, there are a few central 
tenets of Karon’s approach largely in tune with the core psychodynamic principles 
discussed earlier. The first critical issue is how to come into meaningful contact with the 
patient. That is, at the very onset of treatment emotional contact must be established. 
Schizophrenic individuals are good at avoiding authentic contact with people, so in the 
initial sessions it is imperative for the therapist to establish his or her existence, desire to 
help, as well as convey understanding of the patient’s confusing and frightening 
experience. The immense dread often experienced by the patient is diminished if the 
therapist provides attention, interest, and absolute seriousness in the meaning of the most 
frightening psychotic experience of the patient (e.g., projections, hallucinations, 
delusions). There are also two general principles of interpretation adhered to in this 
approach, both intended to generate insight promoting change.  
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The first principle is to interpret from the surface in the sense of exhausting reality 
factors and realistic explanations first. Few patients are willing to consider 
psychodynamic factors until commonsense explanations are found wanting. Driving this 
principle is the basic idea that a therapist interprets what he or she believes the patient can 
make use of at that time. The second general principle is that the therapist never does for 
a patient what the patient can do for him- or herself. An insight discovered by the patient 
is far more potent than a similar interpretation from the therapist. In other words, value 
the meaning-making processes inherent in a patient’s tendency towards health. In terms 
of therapist activity, Karon and VandenBos (1981) assert that it is not accurate empathy 
or understanding that produces change in patients, but rather the therapist’s concerted 
attempts at empathy and understanding (whether or not successful). Also, Karon’s 
approach highlights the importance of the therapist’s capacity to tolerate confusion, due 
not only to the often obscure and entangled thinking of the patient, but also because 
conveying confusion as a tolerable and all-too-human experience is an invaluable 
offering to a person suffering with schizophrenic processes. In sum, Karon’s approach to 
psychotherapy with schizophrenic patients is to value and encourage the totality of 
patients’ successful and troublesome encounters with self and world, to be tolerant and 
kind, create hope, to encourage self-understanding, and perhaps most of all, to be 
stubborn in not accepting therapeutic failure. 
Measure  
Social Cognition and Object Relations Scale (SCORS). Westen's (1995; 
Hilsenroth, Stein, & Pinsker, 2004) SCORS is a narrative-based object relations measure 
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designed to assess a variety of dynamic personality features beyond the overt presentation 
of the patient. The SCORS consists of eight clinician-rated dimensional variables that 
examine the affective and cognitive aspects of an individual's object relations. This 
multivariate approach allows clinicians to discern higher from lower areas of object 
relational functioning. Such an approach is clinically useful considering that people 
generally possess interpersonal strengths and weaknesses contingent upon the content of 
the schema certain social situations activate (e.g., emotional intimacy schema, authority 
schema). Each of the eight SCORS variables is scored on a 7-point anchored rating scale 
where lower scores (e.g., 1 or 2) indicate greater pathology and higher scores (e.g., 6 or 
7) indicate greater psychological health. 
The eight SCORS subscales include: 1) “Complexity of Representations” (COM) 
assesses the richness of a patient’s representations of self and others, as well as his or her 
abilities to integrate both positive and negative attributes of self and others; 2) “Affect 
Tone of Representations” (AFF) assesses a patient’s positive and/or negative expectations 
from others in relationships and how the patient describes relationships; 3) “Emotional 
Investment in Relationships” (EIR) identifies the patient’s level of commitment and 
emotional sharing in relationships; 4) “Emotional Investment in Values and Moral 
Standards” (EIM) distinguishes between patients who show no remorse for selfish actions 
versus those who think about moral questions in genuinely compassionate and thoughtful 
ways; 5)“Understanding of Social Causality” (USC) assesses how well a patient 
understands why people do what they do; 6) “Experience and Management of Aggressive 
Impulses” (AGG) assesses a patient’s ability to control and appropriately express 
aggression; 7) the “Self-Esteem” (SE) variable assesses the affective quality of patient’s 
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self-representation; and 8) “Identity and Coherence of the Self” (ICS) assesses a patient’s 
level of integration and goal-directed behavior. 
Huprich and Greenberg (2003) and Stricker and Gooen-Piels (2004) provide an 
extensive review of previous SCORS research, therefore the following will be an 
illustrative rather than exhaustive presentation of the SCORS’ reliability and validity. The 
SCORS has exhibited good to excellent inter-rater reliability when utilized to rate TAT 
narratives (Ackerman, Clemence, Weatherill, & Hilsenroth, 1999; Ackerman, Hilsenroth, 
Clemence, Weatherill, & Fowler, 2000; Fowler, Ackerman, Speanburg, Bailey, & 
Blagys, 2004), relational and self-statements expressed to clinicians in psychotherapy 
sessions (Peters, Hilsenroth, Eudell-Simmons, Blagys, & Handler, 2006), early memory 
narratives of adult clinical outpatients (Fowler, Hilsenroth, & Handler, 1995; Slavin, 
Stein, Pinsker, & Hilsenroth, in press), semi-structured interview data (Porcerelli, Cogan, 
& Hibbard, 1998), and stories elicited by the Picture Arrangement subtest of the WAIS-R 
(Segal, Westen, Lohr, & Silk, 1993).  
Convergent validity has been demonstrated in a number of studies comparing the 
SCORS to validated research instruments such as the Rorschach Inkblot Method 
(Ackerman, Hilsenroth, Clemence, Weatherill, & Fowler, 2001; Hibbard, Hilsenroth, 
Hibbard, & Nash, 1995) and the DSM-IV Axis V scales (Peters et al., 2006). Previous 
studies have found the SCORS useful for understanding affective aspects of 
psychopathology (Hibbard et al., 1995), patterns of psychotherapy continuation 
(Ackerman et al., 2000), personality change in treatment-refractory inpatients (Fowler et 
al., 2004); interpersonal components of victims of childhood sexual abuse (Callahan, 
Price, & Hilsenroth, 2003; Slavin et al., in press), and differentiating borderline 
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personality disorder outpatients into subgroups (Tramantano, Javier, & Colon, 2003). The 
SCORS has also shown the capacity to discriminate between borderlines, major 
depressives, and normals (Westen, Lohr, Silk, Gold, & Kreber, 1990), MMPI diagnosed 
psychotics, sociopaths, and normals (Porcerelli et al., 1995), inpatient suicide attempters 
and non-attempters (Kaslow et al., 1997), as well as cluster B and cluster C personality 
disorders (Ackerman et al., 1999). The SCORS has also predicted treatment response for 
PTSD diagnosed inpatients (Ford, Fisher, & Larson, 1997) and psychosocial adjustment 
approximately two years after the death of a spouse (Field, Sturgeon, Puryear, Hibbard, 
& Horowitz, 2001).  
Interrater reliability of each of the SCORS subscales was evaluated utilizing a 
one-way random effects model intraclass correlation coefficients (ICC [1,1]; Shrout & 
Fleiss, 1979) from 20 randomly selected pre- or post-treatment protocols across all three 
groups. Raters were two advanced doctoral students enrolled in an American 
Psychological Association approved clinical Ph.D program. Prior to rating the SCORS 
both raters participated in group training in which scoring guidelines were reviewed and 
supervised by a licensed Ph.D Clinical Psychologist. Upon completion of the reliability 
scoring, raters met to discuss any ratings that were separated by two or more points to 
attempt to bring the scores to at least within one point of each other. This additional step 
was necessary due to the degree of cognitive distortion and psychotic psychopathology 
inherent in this schizophrenic sample. All protocols were coded to mask group affiliation, 
name, gender, and time to ensure that ratings were blind throughout the entirety of 
scoring for both raters. Table 3 reports interrater reliability for each of the SCORS’ eight 
subscales. ICCs are considered to be excellent if greater than .74, good from .60 to .74, 
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fair from .40 to .59, and poor if under .40 (Shrout & Fleiss, 1979; Fleiss, 1981). All 
SCORS subscales were in the good to excellent range.   
Explanation of Analyses 
 SCORS variables with appropriate unrestricted variance will be utilized in all 
subsequent analyses. First, to assess the convergent and divergent validity of the SCORS 
for use with a schizophrenic sample, Pearson rs were computed between each of the pre-
treatment SCORS variables and five criterion variables: 1) pre-treatment Clinical Status 
Interviews (CSI); 2) verbal IQ as measured by the WAIS (Weschler, 1955); 3) total days 
in hospital (controlling for treatment change) over the course of the 20 month 
investigation; 4) age; and 5) years of education.  
CSIs were conducted with each patient at pre-treatment by Karon and Vandenbos 
(1981). The CSI is a clinician-rated indicator of overall health-sickness comparable to the 
Global Assessment of Functioning scale found in the DSM-IV (APA, 1994). Similar to 
the SCORS, higher CSI scores indicate healthier levels of functioning. Thus, it was 
hypothesized that the CSI and all SCORS variables would exhibit a positive and 
significant relationship.  
Past research has found that variables COM and USC are the cognitive variables 
of the SCORS measure, as opposed to the other SCORS variables that are deemed the 
affective variables (Hibbard et al., 1995; Westen, 1995). Therefore, in regard to verbal 
IQ, it was predicted that the SCORS’ cognitive variables COM and USC would be 
positively and significantly related to verbal acuity as measured by the WAIS, thereby 
indicating convergent validity. In contrast, in the service of assessing divergent validity, 
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it was hypothesized that AFF, EIR, SE, and ICS would not exhibit a positive and 
significant relationship, since these variables are designed to assess the affective 
components of object relations and are theoretically distinct from IQ. Exhibiting 
divergent validity of a narrative-based measure with verbal acuity is important to ensure 
that the quality of narratives is more related to the construct under investigation (i.e., 
object relations) rather than to verbal skills.  
In regard to the SCORS and total days in the hospital, it was hypothesized that the 
relationship would be significant and in the negative direction. That is, the more days 
spent in the hospital due to poor psychiatric functioning, the lower the pre-treatment 
SCORS ratings. Lastly, in the service of divergent validity, it was hypothesized that age 
and years of education would not be related to object relations. Pearson r correlational 
coefficients are considered to represent a small effect from .1 to .3, a medium effect from 
.3 to .5, and a large effect if greater than .5 (Cohen, 1988).  
Utilizing paired-samples t tests, pre-treatment SCORS variables with appropriate 
unrestricted variance were examined to determine within-group change. This analysis 
assessed whether or not Psychotherapy or Medication treatment led to significant change 
across each SCORS variable. T scores were converted to Cohen’s d effect size to 
facilitate comparison between variables and groups and provide a commonly used 
magnitude of effect coefficient. Cohen’s d values .2, .5, and .8 indicated small, medium, 
and large effects, respectively.  
Following the paired-samples t tests, ‘difference scores’ for each SCORS variable 
were calculated for each SCORS variable at the group level (i.e., post-treatment minus 
pre-treatment). Independent-samples t tests will be conducted to assess between-group 
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differences for each SCORS variable. While these traditional outcome analyses allow for 
determination of gross differences between treatment groups, they are not capable of 
isolating individual patient change. To examine change at the individual patient level pre-
treatment SCORS variables with appropriate unrestricted variance were subsequently 
examined using Clinical Significance (CS) methodology (Jacobson & Truax, 1991; 
Jacobson, Roberts, Berns, & McGlinchley, 1999). Utilization of CS methodology 
provides “valuable information on variability of outcome within each treatment condition 
and a way of determining the practical importance of statistically significant differences 
between groups” and will be used to “descriptively augment” group change examined 
with the independent-samples t tests of ‘difference scores’ (Jacobson et al., p. 301). 
Jacobson and colleagues (1999) write,  
Group means…do not in and of themselves indicate the proportion of participants 
who have improved or recovered as a result of treatment… Standard statistical 
comparisons between groups seldom determine the practical importance of the 
treatment effects… even effect sizes do not directly speak to clinical significance” 
(p. 300).  
In the CS methodology an individual patient is considered ‘Recovered’ if he or 
she meets two criteria: 1) a Reliable Change Index (RCI) score that exceeds 1.96; and 2) 
achieves an outcome score (on the SCORS subscale) that is 2 SDs greater than the 
accepted normative data of the scale in question. Meeting only one or the other criterion 
precludes a researcher from labeling the individual ‘Recovered’. Considering the acutely 
severe presentation of the current patient sample and the increased time it took for these 
patients to seek hospital admission, there are obvious concerns regarding regression to 
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the mean (Fowler et al., 2004). As a result, the Edwards-Nunnally formula (Speer, 1992), 
which was created to control for regression to the mean during the computation of RCI 
scores was applied to adjust all pre-treatment mean scores. 
Criterion 1, calculation of the RCI, is computed in a fashion that controls for 
measurement error, therefore suggesting that the RCI score is both psychometrically 
reliable and reflective of real change, rather than standard error of measurement. For our 
study using the SCORS, a modification in the RCI formula was necessary because test-
retest reliability, which is unavailable for the SCORS, is most commonly used to 
determine the standard error of difference (Sdiff) found in the denomination of the RCI 
formula (Wise, 2004). Jacobson et al. (1999) propose utilization of alternative measures 
of reliability for the calculation of Sdiff.  Hilsenroth, Ackerman, Blagys, Baity, & 
Mooney, (2003) and Fowler et al. (2004) have made use of this suggestion in two 
recently published outcome studies by using ICCs as an alternative reliability coefficient 
in calculating Sdiff.  For the purpose of this dissertation project ICCs will be used in a 
like manner.  
In regard to criterion 2, just as there are no normative test-retest data for the 
SCORS, there are also no available normative means for its subscales. Fortunately, other 
authors have proposed (Bauer, Lambert, and Nielsen, 2004) and utilized (Fowler et al., 
2004; Hilsenroth et al., 2003) an alternative method for computing a post-treatment 
outcome score cutoff point. This cutoff point is determined by taking the pooled pre-
treatment sample mean of each target variable (i.e., the SCORS subscale) and adding two 
SDs. For example, if the pooled mean of the Complexity of Representations variable was 
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2.01 with a SD of .67, the outcome score of this variable for an individual patient must 
exceed 3.35 (i.e., 2.01 + [.67 * 2]) to meet the condition needed to satisfy criterion 2.   
One last modification is necessary due to the severity of our sample. Wise (2004) 
observed that it is unrealistic to expect a sample of severely disturbed patients to achieve 
the clinically significant benchmarks of RCI > 1.96 and an outcome cutoff point two SDs 
greater than the pre-treatment mean. As such, Wise (2004) recommended additional 
criteria for both RCI scores and standard deviation cutoff points. Wise’s (2004) 
alternative is termed ‘Positive Response’ and requires that a patient achieve an RCI > 
1.28 (i.e., the 90% confidence interval for RCI) and an outcome cutoff point one SD 
greater than the pre-treatment mean. In their study of treatment-refractory inpatients, 
Fowler et al. (2004) utilized Wise’s (2004) alternative criteria in addition to Jacobson and 
Truax’ (1991) original classification (RCI > 1.96 and SD > 2.0). Based on our severely 
disturbed schizophrenic sample, the current evaluation has also focused on both change 
estimates classified as ‘Recovered’ and ‘Positive Response’. Percentages of patients in 
each group meeting these two criteria were computed for all six SCORS variables. Rates 
of clinical regression follow the same criteria but in the opposite direction and they too 
are reported. Examining regression (if any) is particularly significant due to the widely 
held belief that psychodynamic psychotherapy of schizophrenia is dangerous and results 
in clinical regression (e.g., Lehman & Steinwachs, 1998).  
An additional manner in which to understand how the patients of the current 
sample presented clinically at post-treatment can be accomplished by comparing post-
treatment SCORS scores to alternative SCORS data derived from another study that 
investigated a less disturbed sample. For such a purpose, Table 4 reports pre-treatment 
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SCORS subscale data from a study investigating the object relations of a patient sample 
seeking psychotherapy from a university-based mental health center (Peters et al., 2006). 
Peters and colleagues reported that the “level of psychological/emotional distress of the 
patients in this treatment program was primarily in the mild to moderate range of 
impairment, as evidenced by the DSM-IV  (American Psychiatric Association, 1994) 
diagnostic categories, clinician rating scales, and self-report measures” (p. 618). Thus, if 
the outcome SCORS ratings of any schizophrenic patients equal or exceed the SCORS 
ratings of this markedly healthier sample, it can be cautiously suggested that, at post-
treatment, the object relations of these patients are comparable to patients entering 
psychotherapy with mild to moderate levels of distress. Providing this auxiliary 
information is another manner by which to show whether or not schizophrenics receiving 
medication–only or psychotherapy-only are capable of improving in a manner contrary to 
the expectations set forth by the biopsychiatric model.  
While comparing percentages of those patients meeting ‘Recovered’ and ‘Positive 
Response’ criteria provide important clinical information, application of chi square 
analyses would provide a measure of statistical significance for group differences. 
However, to perform the necessary 12 chi square analyses for all six subscales testing for 
group differences using ‘Recovered’ and ‘Positive Response’ criteria would greatly 
increase the risk of making a Type I error. Ford and colleagues (1997) and Peters et al. 
(2006) have previously used a composite object relations score as a variable. This 
procedure was adopted for the present study to limit the number of performed analyses in 
an attempt to minimize the possibility of a Type I error. SCORS-Composite (SCORS-C) 
was calculated by simply summing each of the SCORS variables and dividing by the 
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number of variables summed to produce a single 7-point object relations total score. RCI 
scores and improvement status (‘Recovered’ and/or ‘Positive Response’) were calculated 
using the same procedures described above for the individual SCORS subscales. Chi 
square scores were converted to Cohen’s d effect size to facilitate comparison between 
variables and provide a commonly used magnitude of effect coefficient.  
Lastly, to statistically test for group differences in clinical change after 
controlling for error measurement and regression to the mean, independent-samples t 
tests were computed using RCI scores as the dependent variable and group assignment as 
the grouping variable. Again, because the RCI score is both psychometrically reliable and 
reflective of real change, rather than standard error of measurement or regression to the 
mean, it is a particularly useful indicator of clinical change and a statistical improvement 
over past outcome research that historically has not controlled for such artifacts. In this 
way, independent-samples t tests using RCI as the dependent variable might be a more 
reliable and accurate indicator of group change compared to the traditional ‘difference 
score’ analyses also conducted in this study. T-scores were converted to Cohen’s d effect 
size to facilitate comparison between variables and provide a commonly used magnitude 
of effect coefficient.  
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III. RESULTS 
 The EIM (SD = .22) and AGG (SD = .24) variables (combined groups) did not 
exhibit suitable unrestricted variance at pre-treatment and were thus removed from 
subsequent analyses. The SDs of the other six SCORS variables ranged from .49 - .81, 
thus the SDs for EIM and AGG were observably restricted. As a result, only six of the 
eight SCORS subscales will be utilized in all subsequent analyses (COM, AFF, EIR, 
USC, SE, and ICS). There were no significant between-group differences for any of the 
six pre-treatment SCORS variables or demographic variables (education, age, gender, 
race) confirming the randomness of group assignments.  
Convergent and Divergent Validity 
Table 5 reports all convergent and divergent validity analyses utilizing the pre-
treatment SCORS ratings. As expected, the WAIS Verbal Scale IQ (n = 17) and the 
SCORS’ COM (r = .52, p = .03) and USC (r = .45, p = .01) exhibited significant and 
moderate to large effects, indicating that the SCORS’ cognitive variables were 
appropriately related to verbal intelligence. In regard to divergent validity, as expected, 
the SCORS’ affective variables were not related to verbal IQ, indicating that the SCORS 
affective variables measure something distinct from verbal functioning. In regard to 
convergent validity, the CSI (n = 21) and the pre-treatment SCORS variables COM (r = 
.79, p < .0001), USC (r = .71, p < .0001), and ICS (r = .59, p = .005) all exhibited 
significant and large effects. Pearson rs of the CSI and the pre-treatment SCORS 
variables AFF (r = .50, p = .02) and SE (r = .48, p = .03) exhibited significant and 
moderate effects. SCORS variable EIR (r = .42, p = .06) approached significance with a 
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moderate effect. Associations between the pre-treatment SCORS subscales and total days 
in the hospital (n = 21) further substantiate the convergent validity of the SCORS for use 
with this uniquely disturbed cohort. Pearson r partial correlations for total days in 
hospital and the pre-treatment SCORS variables COM (r = -.57, p = .009), USC (r = -.66, 
p = .002), and ICS (r = -.68, p = .001) all exhibited significant and large effects in the 
appropriate negative direction. Pearson r partial correlations for total days in hospital and 
the pre-treatment SCORS variables AFF (r = -.38, p = .10) and EIR (r = -.39, p = .09) 
approached significance with moderate effects in the appropriate negative direction.  
Within-Group Analyses of Change 
Paired-samples t tests illustrate pre- to post-treatment within-group change across 
all six SCORS variables for both the Psychotherapy (Table 6) and Medication (Table 7) 
groups. Patients in the Psychotherapy group exhibited significant change with robust 
effects across all six object relations constructs (COM t[8] = 4.46, p = .002, d = 3.15; 
AFF t[8] = 3.89, p = .005, d = 2.75; EIR t[8] = 2.39, p  = .04, d = 2.39; USC t[8] = 6.53, p 
= .0001, d = 4.62; SE t[8] = 4.53, p = .002, d = 3.20; and ICS t[8] = 5.01, p = .001, d = 
3.54). Overall mean Cohen’s d effect size for the Psychotherapy group was large at 3.28. 
Comparatively, patients of the Medication group did not fare as well relative to patients 
receiving psychodynamic psychotherapy. Only two of six variables in the Medication 
group reached statistical significance for pre- to post-treatment change (COM t[11] = 
2.67, p = .02, d = 1.61 and EIR t[11] = 3.29, p  = .007, d = 1.98). SCORS variables USC 
t[11] = 2.04, p = .07, d = 1.23 and ICS t[11] = 1.74, p = .11, d = 1.05 approached 
significance. Considering the small group size (and thus limited power), the results for 
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the latter two variables may be indicative of a significant change. Liberally, these effect 
sizes will be included in the Medication group’s mean effect size. The effect sizes of the 
non-significant variables will be set to zero for this calculation. As such, overall mean 
Cohen’s d effect size for the Medication group was .98. 
Traditional Analyses of Between-Groups Change Using ‘Difference Scores’ 
 Traditional analyses of between-groups change found that psychodynamic 
psychotherapy for schizophrenia is superior to medication-only for treating schizophrenia 
across multiple object relations domains (Table 8). Differences between treatments were 
significant for three of six SCORS variables with large effects (COM t[19] = 2.27, p = 
.04, d = 1.05; USC t[19] = 2.61, p = .02, d = 1.21; and SE t[19] = 2.40, p  = .03, d = 
1.13). SCORS variables AFF t[19] = 1.94, p = .07, d = .90 and ICS t[19] = 1.65, p = .12, 
d = .77 both approached significance with a large and medium effect, respectively. 
Considering the small sample size (and thus limited power) used in these analyses, the 
results for the latter two variables may be indicative of significant between-groups 
treatment effects. The SCORS variable EIR did not exhibit a statistically significant 
between-groups effect (p = .86). 
‘Recovered’ and/or ‘Positive Response’ to Treatment 
Table 9 reports improvement and deterioration rates of the Psychotherapy and 
Medication patients for the SCORS subscale Complexity of Representation (COM). 
Utilizing Jacobson and Truax’ (1991) conservative estimates of recovery (i.e., RCI > 1.96 
and SD > 2.0), 56% (5/9) of Psychotherapy patients met criteria for recovery in regard to 
a multi-dispositional and differentiated view of self and others. An even more 
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conservative estimate of recovery would be the 22% (2/9) of patients who achieved an 
RCI > 1.96 and reached the pre-treatment mean of the patients represented in Peters et al. 
(2006). In comparison, 42% (5/12) of the Medication patients met the conservative 
estimate of recovery for COM. However, unlike the Psychotherapy group, no medicated 
patients achieved the RCI > 1.96 score and pre-treatment mean of the patients represented 
in Peters et al. (2006).   
Table 10 reports improvement and deterioration rates of the Psychotherapy and 
Medication patients for the SCORS subscale Affect Tone of Representations (AFF). 
Conservative estimates of recovery found that 11% (1/9) of Psychotherapy patients met 
criteria for improvement in their expectations of other as benevolent and helpful. 
Interestingly, 33% (3/9) of the Psychotherapy patients achieved an RCI > 1.96 and 
reached the pre-treatment mean of the patients in Peters et al. (2006), indicating that a 
third of the Psychotherapy group ended treatment comparable to an average outpatient in 
regard to affective expectations of others. No Medication patients met the Jacobson and 
Truax’ (1991) conservative estimates of recovery or the RCI > 1.96 in combination with 
the pre-treatment mean of the patients represented in Peters et al. (2006). 
Table 11 reports improvement and deterioration rates of the Psychotherapy and 
Medication patients for the SCORS subscale Emotional Investment in Relationships 
(EIR). Conservative estimates of recovery found that 33% (3/9) of Psychotherapy 
patients met criteria for improvement in regard to their desire to invest themselves 
emotionally in interpersonal relationships. More conservatively, only 11% (1/9) of 
psychotherapy patients achieved an RCI > 1.96 and reached the pre-treatment mean of 
the patients in Peters et al. (2006). In comparison, 17% (2/12) of the Medication patients 
 96
met the conservative estimate of recovery, and only 8% (1/12) of the medicated patients 
achieved an RCI > 1.96 and reached the pre-treatment mean of the patients in Peters et al. 
(2006).  
 Table 12 reports improvement and deterioration rates of the Psychotherapy and 
Medication patients for the SCORS subscale Understanding of Social Causality (USC). 
Conservative estimates of recovery found that 44% (4/9) of Psychotherapy patients met 
the criteria for improvement in regard to their capacity to determine why people behave 
the way they do in the interpersonal field. That is, nearly half of the Psychotherapy 
patients by treatment’s end were significantly better equipped to read the motivation and 
behavior of others, largely ameliorating one of the defining features of schizophrenic 
suffering: the inability to realistically assess one’s social world. An even more 
conservative estimate of recovery would be the 22% (2/9) of patients who achieved an 
RCI > 1.96 and reached pre-treatment mean of the patients in Peters et al. (2006). In 
comparison, 25% (3/12) of Medication patients met the conservative estimate of 
recovery. Unlike the Psychotherapy group, no Medication patients achieved an RCI > 
1.96 and reached pre-treatment mean of the patients in Peters et al. (2006).     
  Table 13 reports improvement and deterioration rates of the Psychotherapy and 
Medication patients for the SCORS subscale Self-Esteem. Conservative estimates of 
recovery found that 22% (2/9) of Psychotherapy patients met criteria for improvement in 
their experience of self-esteem. Of note, 56% (5/9) of Psychotherapy patients achieved an 
RCI > 1.96 and reached the pre-treatment mean of the patients in Peters et al. (2006). 
That is, by treatment’s end, over half of the Psychotherapy patients had as much self-
esteem as a mild to moderately severe clinical sample typical of an outpatient, university-
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based psychotherapy clinic. In comparison, no medication patients met Jacobson and 
Truax’ (1991) conservative estimates of recovery for Self-Esteem nor did any medicated 
patients achieve an RCI > 1.96 and reach the pre-treatment mean of the patients in Peters 
et al. (2006). 
Table 14 reports improvement and deterioration rates of the Psychotherapy and 
Medication patients for the SCORS subscale Identity and Coherence of the Self (ICS) 
Conservative estimates of recovery found that 11% (1/9) of Psychotherapy patients met 
criteria for improvement in their experience of themselves as moving forward in the 
world with goals and a coherent, temporally stable sense of self. Of note, 67% (6/9) of 
Psychotherapy patients achieved an RCI > 1.96 and reached the pre-treatment mean of 
the patients in Peters et al. (2006). That is, by treatment’s end, two-thirds of the 
Psychotherapy patients subjectively experienced themselves as an individual with a 
personality as well integrated and as non-psychotic as patients seeking outpatient 
psychotherapy. In comparison, no medication patients met Jacobson & Truax’ (1991) 
conservative estimates of recovery while 25% (3/12) achieved an RCI > 1.96 and reached 
the pre-treatment mean of the patients in Peters et al. (2006). 
Table 15 reports improvement and deterioration rates of the Psychotherapy and 
Medication patients for the SCORS composite variable (SCORS-C). Conservative 
estimates of recovery found that 44% (4/9) of Psychotherapy patients met criteria for 
improvement in their overall object relations. In comparison, only 8% (1/12) of 
medication patients met Jacobson & Truax’ (1991) conservative estimates of recovery in 
regard to overall object relations change. 
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As can be viewed in Tables 9-15, for all six SCORS variables and SCORS-C, 
rates of improvement rose for the Psychotherapy patients when the criteria were relaxed 
according to Wise’s (2004) alternative ‘Positive Response’ criteria (RCI > 1.28 and SD > 
1.0). Rates of ‘Positive Response’ to psychodynamic psychotherapy were as follows: 
Complexity of Representations (7/9, 78%); Affect Tone of Representations (3/9, 33%); 
Emotional Investment in Relationships (5/9, 56%); Understanding of Social Causality 
(7/9, 78%); Self-Esteem (4/9, 44%); Identity and Coherence of the Self (6/9, 67%); and 
SCORS-C (7/9, 78%).  
In regard to the Medication group, as can be viewed in Tables 9-15, rates of 
improvement generally - though not across the board - rose when the criteria were 
relaxed according to Wise’s (2004) alternative ‘Positive Response’ criteria (RCI > 1.28 
and SD > 1.0). Rates of ‘Positive Response’ to medication were as follows: Complexity 
of Representations (5/12, 42%); Affect Tone of Representations (1/12, 8%); Emotional 
Investment in Relationships (5/12, 42%); Understanding of Social Causality (6/12, 50%); 
Self-Esteem (3/12, 25%); Identity and Coherence of the Self (4/12, 33%); and SCORS-C 
(4/12, 33%).  
Contrary to the PORTs negative expectations, it is important to note that whereas 
no Psychotherapy patients exhibited clinically significant regression either at the 
conservative or more relaxed criteria, there were in fact Medication patients who 
exhibited clinically significant regression when inverting Wise’s (2004) ‘Positive 
Response’ criteria (i.e., ‘Negative Response’). For Medication patients, 8% (1/12) 
exhibited a ‘Negative Response’ for COM, AFF, EIR, ICS, SE, and SCORS-C. Similar to 
conservative rates of improvement using Jacobson and Truax’ (1991) ‘Recovered’ 
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criteria, the Psychotherapy patients also fared better (percentage wise) on all variables 
when using Wise’s (2004) ‘Positive Response’ criteria.  
In regard to significance tests for SCORS-C, chi square analyses examining group 
differences indicated results approaching significance with a large effect for number of 
‘Recovered’ patients (χ2 = 3.70, p = .12, d = .93) as well as ‘Positive Response’ patients 
(χ2 = 4.07, p = .08, d = .98). Considering the small sample size (and thus limited power) 
of the present study, these results may be indicative of a significant and clinically 
relevant difference between groups. 
As mentioned, no patients receiving psychodynamic psychotherapy exhibited 
clinically significant regression. In fact, any sign of regression indicated by a negative 
RCI score was relatively rare for patients receiving psychodynamic psychotherapy. Out 
of 63 computed RCI scores (i.e., nine patients multiplied by six SCORS variables and 
SCORS-C) only 4 had a negative value (6%). In fact, for SCORS-C, not only were there 
no psychotherapy patients with a negative RCI score, only one patient had a SCORS-C 
RCI score below 1.00. This degree of consistent positive performance was not true of the 
Medication group for which 25 of 84 RCI scores (30%) exhibited clinical regression. 
Furthermore, 25% (4/12) of Medication patients had a negative RCI score for SCORS-C, 
and, as mentioned, one Medication patient exhibited clinically significant regression for 
the inversion of Wise’s ‘Positive Response’. A post hoc chi square analysis found that the 
between-group difference in regard to presence of a negative treatment response as 
indicated by a negative SCORS-C RCI was approaching significance with a large effect 
(χ2 = 3.71, p = .10, d = .93). Considering the small sample size (and thus limited power) 
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of the present study, these results may be indicative of a significant and clinically 
relevant difference between groups. 
Group Differences for RCI Scores 
To maintain the optimal clinical utility of the present study, it was important to 
also test for group differences on each of the six SCORS variables while controlling for 
error measurement and regression to the mean. Providing data on these individual 
variables offers practicing clinicians tangible, real-world information applicable to 
clinical practice and therefore maintains the generalizability of the study. That is, it is 
clinically useful to know if one treatment or the other specifically impacts a particular 
dimension of object relations after controlling for artifacts. Table 16 reports the results of 
independent-samples t tests conducted for all six SCORS variables to determine if the 
Psychotherapy and Medication groups differed in regard to degree of change as measured 
by the RCI. Again, because the RCI is reflective of real change and not the product of 
measurement error it is a particularly useful indicator of clinical progress. Three of six 
SCORS RCI values exhibited statistically significant and large differences between the 
Psychotherapy and Medication groups. As can be seen by the RCI means in Table 16, all 
results favored the Psychotherapy patients (COM, t[19] = 2.08, p = .05, d = .92; USC 
t[19] = 2.44, p = .03, d = 1.08; and SE t[19] = 2.45, p = .02, d = 1.08). Two of six SCORS 
RCI values approached statistical significance with large effects between the 
Psychotherapy and Medication groups (AFF, t[19] = 2.01, p = .06, d = .89; ICS t[19] = 
1.81, p = .09, d = .80). Again, considering the small sample size (and thus limited power) 
of the present study, the results for the latter two variables may be indicative of a 
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significant and clinically relevant difference between groups. The SCORS variable EIR 
did not exhibit a statistically significant between-groups effect (p = .71). These results are 
consistent with the traditional ‘difference score’ analyses presented in Table 8, though 
after controlling for error measurement and regression to the mean, as can be seen by 




For far too long the empirical evidence supporting the positive effects of 
psychodynamic psychotherapy for the treatment of schizophrenia has been neglected due 
to a few core assumptions. As a result, there has been little space for its regular inclusion 
in research; furthermore, its clinical application in standard treatment has been 
diminishing for years.  
First, the degenerative brain disease assumption has inculcated the idea in the 
mental health profession that schizophrenia can only be managed rather than cured. As 
extensively presented above, substantial evidence contradicts this notion on the grounds 
that 1) the 19th century derived schizophrenia concept is grounded in often 
unacknowledged non-epistemic ideas such as degeneration theory and philosophical 
realism that serve to distort current conceptualization and treatment approaches; 2) 
research investigating the effects of the duration of untreated schizophrenia has not 
reliably shown a psychotoxic effect on the brain, nor has it been related to clinical 
regression; and 3) ample longitudinal, cross-cultural data exist that document significant 
improvement and recovery for people suffering with schizophrenia.  
The second assumption is the supposed superiority and safety of medication 
treatment for schizophrenia. Despite limited empirical backing, this assumption has been 
reproduced continuously since the 1950s. In contrast, substantial evidence presented 
earlier suggests that medications are of limited effectiveness, undeniably dangerous in 
regard to an array of side-effects and may even preclude clinical progress/recovery.  
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The third assumption, that is, the alleged ineffectiveness of psychodynamic 
psychotherapy, has been directly stated in the schizophrenia Patient Outcome Research 
Team study (PORT; Lehman & Steinwachs, 1998), a recent schizophrenia treatment 
guideline published by biologically-based clinicians and researchers. PORTs 
Recommendation 22 reads,  
Individual and group psychotherapies adhering to a psychodynamic model 
(defined as therapies that use interpretation of unconscious material and focus on 
transference and regression) should not be used in the treatment of persons with 
schizophrenia… there is a consensus that psychotherapy that promotes regression 
and psychotic transference can be harmful to persons with schizophrenia (pp. 7-8; 
my emphasis).  
Since the PORT project was convened to review the clinical outcome literature to create 
treatment guidelines for practicing psychiatrists and psychologists, this misperception is 
extremely significant. Ver Eecke (2003), Gottdiener and Haslam (2003), and Silver 
(2003) provide a clear, empirically- and theoretically-based critique of the mistaken 
conclusions of the PORT. The results of the current investigation add weight to their 
important criticism and directly challenge this flawed and widespread assumption. 
 Speaking directly to the empirical results of this dissertation project, there are four 
major findings. First, the SCORS exhibits satisfactory inter-rater reliability for use with a 
schizophrenic sample. Second, the SCORS, in a preliminary fashion, exhibits adequate 
convergent and divergent validity for use with a schizophrenic sample. Third, contrary to 
the PORTs admonishments that psychodynamic psychotherapy for the treatment of 
schizophrenia is “harmful”, the results of this study indicate that psychodynamic 
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psychotherapy is capable of providing reliable clinical change in the object relations of 
schizophrenic patients. Fourth, in comparison to medication-only treatment, 
psychodynamic psychotherapy results in significantly greater improvement in a variety of 
object relations domains for patients suffering with schizophrenia.   
Reliability estimates for the current investigation are consistent with past research 
regarding the interrater reliability of the SCORS variables (e.g., Fowler et al., 2004). 
Importantly, although the SCORS has been used to rate a diverse array of clinical and 
non-clinical samples, as far as can be determined this is the first study to apply the 
SCORS to a strictly schizophrenic sample. Thus, this study extends previous research 
since the current findings indicate the SCORS can reliably measure TAT narratives 
collected from severely psychotic individuals.  
Correlational analyses helped illuminate preliminary divergent and convergent 
validity of the SCORS for use with a psychotic sample. As expected, the affective 
SCORS variables were unrelated to verbal functioning. This finding is important because 
it is imperative that a narrative-based measure maintains its independence from verbal 
acuity so that an individual’s capacity to verbalize him- or herself does not 
disproportionately obscure accurate assessment of other constructs under investigation. 
Further, support for the SCORS’ independence from verbal IQ is important due to the 
fact that Karon and Vandenbos (1981) have already reported group differences for IQ in 
their original study. Thus, the divergent validity observed in the present investigation 
allows for analysis and reporting of non-redundant clinical outcome data. Divergent 
validity was further supported since there were no significant correlations between the 
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SCORS and age or education, as hypothesized. In sum, results provide preliminary 
divergent validity evidence for use of the SCORS with a strictly psychotic sample.       
As hypothesized, the SCORS’ cognitive variables (COM and USC) were related 
to a commonly used measure of verbal IQ, suggesting that the SCORS can provide valid 
measurement of cognitive processes such as verbal production. Also consistent with the 
theoretical nature of the SCORS, correlational results with clinical status interviews (CSI) 
and days spent in the hospital throughout the duration of the 20-month study exhibited 
significant and moderate to large effect sizes. Determining SCORS object relations 
variables capable of predicting inpatient stays may aid treatment planning by highlighting 
particularly important areas of functioning worth focusing on to avoid hospitalizations. 
The results of this study suggest that clinical attention to patients’ accurate appraisal of 
social interactions (USC), degree of complex understanding of self and others (COM), 
goal-directed behavior across time (ICS), affective expectations of others (AFF), 
emotional investment in interpersonal relationships (EIR), as well as issues of self-esteem 
are all potentially important areas of treatment focus that might prevent or decrease the 
need for hospitalization.   
Previous studies have found the SCORS to be a useful indicator of process 
variables such as treatment continuation (Ackerman et al., 2000), suicidality (Kaslow et 
al., 1997), childhood sexual abuse (Callahan, Price, & Hilsenroth, 2003; Slavin, Stein, 
Pinsker, & Hilsenroth, 2007), social, vocational, and symptomatic functioning (Peters et 
al., 2006), and mourning and loss (Field, Sturgeon, Puryear, Hibbard, & Horowitz, 2001), 
all of which are highly relevant to the treatment of schizophrenia. Thus, the reliability and 
validity results of this investigation represent a promising beginning for use of the 
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SCORS in future process and outcome schizophrenia research. Inclusion of this widely 
validated instrument capable of measuring personality processes beyond overt 
symptomatic distress would also be a significant improvement over the majority of 
schizophrenia outcome studies that overwhelmingly rely on self-report measures of 
positive and negative symptoms, or, simply, medication compliance.  
In regard to outcome, the current investigation replicates past results documenting 
the effectiveness of psychodynamic psychotherapy for the treatment of schizophrenia 
(see for a review Gottdiener & Haslam, 2002). However, this study is fairly unique in 
contemporary research in that data for a completely non-medicated group is provided for 
comparative purposes with a medication-only group. As a result, this study has been able 
to test and, in the end, contest two important assumptions of the recent PORT study, 
namely:  1) that psychodynamic psychotherapy of schizophrenia is “harmful”; and 2) that 
medication treatments are preferable.  
First, in regard to the psychotherapy of schizophrenia being “harmful”, the 
present findings clearly indicate that psychotherapy was not harmful, but, to the contrary, 
resulted in clinically reliable and valid change in both individual and group analyses 
across all of the object relations constructs measured including a patients’ understanding 
of the internal motivations, thoughts, and feelings of self and others (COM), emotional 
investment in relationships (EIR), accurate appraisal of social interactions (USC), more 
benevolent affective expectations of others (AFF), greater levels of self-esteem (SE), 
more coherent sense of identity across time (ICS), and healthier global object relations 
(SCORS-C). Far from being harmful, CS methodology assessing individual patients’ 
progress revealed that an impressive percentage of psychodynamic psychotherapy 
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patients across all variables met ‘Positive Response’ (33-78%) and/or ‘Recovered’ (11-
56%) criteria. These results extend Karon & Vandenbos’ (1981) original findings that 
found psychodynamic psychotherapy to be effective for treating the thought disorder 
component of schizophrenia into the broader realm of interpersonal and self functioning 
as measured by the SCORS. These within-group positive outcome results stand with or 
without comparison to a medication-only group. This is a highly significant point 
because a likely critique of the current design was the use of the older, typical 
medications as opposed to the newer atypicals. However, as discussed above, such a 
critique is empirically untenable due to the majority of clinical research that has found no 
particular clinical advantages of the newer neuroleptic medications (e.g., the CATIE 
study).  
An additional empirical test of the PORT’s claim that psychodynamic 
psychotherapy is harmful was carried out via a post hoc analysis of group differences 
testing an indicator of clinical regression (i.e., negative RCI scores). In direct contrast to 
the PORT’s claim, this analysis found that the number of Medication patients exhibiting a 
negative RCI score on a measure of global object relations (SCORS-C) was significantly 
greater than Psychotherapy patients. That is, regarding object relations change the 
medication-only approach and not psychodynamic psychotherapy appeared to place 
patients at greater risk for clinical regression and of course physiological side-effects for 
which there are none for psychotherapy.  
Unlike the psychotherapy patients, results for medication patients were 
inconsistent as indicated by within-group and individual analyses. When assessed as a 
group (Table 7), Medication patients failed to exhibit group change in regard to Affect 
 108
Tone of Representations and Self-Esteem, two areas that were significantly and positively 
impacted by psychodynamics psychotherapy. In regard to individual analyses using CS 
methodology, while nearly every patient in the Psychotherapy group showed some degree 
of positive improvement across all SCORS variables (i.e., as indicated by a positive RCI 
score), this cannot be said of the Medication patients. This is to say, some Medication 
patients did well on a few variables but not all, and, more problematically, some 
Medication patients simply did poorly across the board. Empirically, this helps explain 
statistically significant group differences for both ‘difference scores’ (Table 8) and RCI 
scores (Table 16) favoring the psychodynamic psychotherapy patients for SCORS 
variables COM, USC, SE, AFF, and ICS, in addition to the overall number of patients 
exhibiting ‘Recovered’ and ‘Positive Response’ criteria for SCORS-C.  
The less consistent outcome of the Medication patients suggests that while 
medication treatment can be helpful for some patients, its generalized, non-specific 
qualities might suggest a certain ‘hit or miss’ phenomenon. This seems to be the case in 
this sample despite psychiatrists who made numerous medication adjustments based on 
their expert, biological-based understanding of schizophrenia. In fact, because medication 
treatments are of course not capable of handling the idiosyncratic thematic issues 
troubling a patient, it would be unreasonable to expect medication to provide an 
ameliorative effect for a patient’s interpersonal, self-esteem, and identity concerns among 
a multitude of other complex issues gravely impacting a person suffering with 
schizophrenia. However, in stark contrast and as many have theoretically suggested (e.g., 
Fromm-Reichmann, 1950), the capacity for a therapist to engage a patient as a complex 
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person with unique difficulties and a life-story to share may be the driving curative factor 
in psychotherapeutic work.  
The erratic outcome and more significant regression observed for the Medication 
patients are not particularly surprising. Writing in the New England Journal of Medicine 
Goldstein (2003 notes, “One of the most striking features of modern medicines is how 
often they fail to work. Even when they do work, they are often associated with serious 
adverse reactions” (p. 553). The relatively high regression of the Medication patients 
found in the present study is also consistent with the extraordinarily high early 
discontinuation rates found in contemporary medication research (e.g., 74%) which 
stands as another indicator of medication intolerability and ineffectiveness (Lieberman et 
al., 2005). Of course, the empirically invalid assumption that safe and effective 
alternatives such as psychodynamic psychotherapy do not exist limits treatment choices 
and fosters the pessimistic submission that medication and their associated drawbacks 
are, so to speak, ‘all that’s out there’. The results of this study, as well as other empirical 
investigations of the effectiveness of psychodynamic psychotherapy strongly suggest 
otherwise.   
Investigating the results more closely, a few more important issues surface which 
are highly relative to the comparative effectiveness of the interventions in question. To a 
degree, and usually on a temporary basis, medication treatments have been shown to 
minimize the positive symptoms of schizophrenia such as disorganized and delusional 
thinking as well as hallucinations. Though, as presented above, such treatment successes 
are often overestimated due to uncontrolled-for statistical confounds such as abrupt drug 
withdrawal, clinically impractical exclusion criteria, multiple prescribing practices, 
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excessive early discontinuation, and psychological and physiological impact of side-
effects (Karon, 1989; Jackson, 2005; Thornley & Adams, 1998). Nonetheless, despite 
such confounds, decrease of positive symptoms via medication seems to be the one fairly 
consistent and positive result of medication research and treatment. Indeed, in the present 
study, most medication patients fared acceptably according to the SCORS cognitive 
variables COM and USC. Nonetheless, the psychotherapy patients fared significantly 
better for these variables. That is, psychotherapy outperformed medications in the very 
area medications are expected to function most effectively. This is a key finding 
considering that there is also considerable evidence that long- and short-term neuroleptic 
use may actually harm cognitive functioning in a variety of domains (Kasper & Resinger, 
2003; Minzenburg et al., 2004; Gilbertson & van Kammen, 1997; Mehta, Manes, 
Magnolfi, Sahakian, & Robbins, 2004; Papageorgiou et al., 2003; Sweeney, Keilp, Haas, 
Hill, & Weiden, 1991; Vitiello et al., 1997; Cassens, Inglis, Appelbaum, & Gutheil, 1990; 
King, 1994; Ridout & Hindmarch, 2003; Brebion, Amador, Smith, & Gorman, 1998; 
Cleghorn, Kaplan, Szechtman, Szechtman, & Brown, 1990; Rammsayer, 1997; McCartan 
et al., 2001; Scherer et al., 2004), thus making viable non-biological alternatives an 
imperative.     
Unlike the partial success of medications for improving the positive symptoms 
associated with schizophrenia, it is well documented that neuroleptic use – typical or 
atypical – does little to ameliorate the debilitating negative symptoms associated with 
schizophrenia (Jackson, 2005). This study builds upon this widely accepted empirical fact 
and provides additional evidence that it might be unrealistic to expect medication 
treatment to positively impact object relations domains such as self-esteem, affective 
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expectation of others, and identity and coherence of self, all of which are dramatically 
impacted by negative symptoms such as social withdrawal, depressive collapse, 
anhedonia, alogia, and avolition. Indeed, in these object relations domains 
psychodynamic psychotherapy outperformed the medication group on all accounts. 
Considering convergent validity results suggesting that such factors may also be potential 
predictors of hospitalization, the role of psychodynamic psychotherapy for schizophrenia 
may not only be clinically valuable in regard to mental health and overall quality of life, 
but economically beneficial as well (Warner, 2004).  
It should be recalled that there were a number of factors working against the 
psychotherapy patients that may render the positive and comparably superior results of 
this type of treatment an underestimation of the potential effectiveness of psychodynamic 
psychotherapy. These factors include inexperienced therapist trainees, Caucasian 
therapists treating and attempting to relate/engage generally inner-city African-American 
patients during the time of the Detroit race riots in the 1960s, fairly chronic rather than 
early episode patients and, on average, only one session per week as opposed to the 2-3 
times per week recommended by most clinicians experienced in the psychotherapy of 
schizophrenia (e.g. Sullivan, 1962). Therefore, even under these difficult circumstances 
psychodynamic interventions appear quite capable of providing substantial clinical 
benefit over and above the effects of medication-only treatment.  
Due to the growing evidence of the danger and ineffectiveness of neuroleptic 
treatment for schizophrenia, many psychologists, and perhaps even more importantly, 
psychiatrists and the news media are beginning to question the degenerative as well as the 
‘medicate continuously and as early as possible’ assumptions. In a 2006 New York Times 
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(NYT) interview, Dr. William Carpenter, director of the University of Maryland’s 
Psychiatric Research Center and editor of the journal Schizophrenia Bulletin reports, “My 
personal view is that the pendulum has swung too far, and there’s a knee-jerk reaction out 
there that says that any period off medication, even for research, is on the face of it 
unethical” (my emphasis). Oddly, in this same NYT interview, despite his own co-
authored meta-analysis that found no association between untreated schizophrenia with 
neurocognitive deficits, morphological changes in the brain, or symptom relapse (i.e., 
Perkins et al., 2005), Dr. Jeffrey Lieberman responds,  
I am usually a pretty moderate person. But on this I am 110 percent emphatic: If 
the diagnosis is clear, not treating with medication is a huge mistake that risks the 
person’s best chance at recovery. It’s just flat out nuts.  
Beyond his own meta-analytic findings refuting his comments, there are many 
longitudinal and psychotherapy outcome studies indicating that not medicating can be 
equally and even more helpful than medication treatments. In fact, as shown above, 
reviews of the schizophrenia outcome literature suggest that exposure to neuroleptic 
medications may negatively impact treatment outcome and even preclude recovery. 
    It is clear that due to the complexity inherent in any treatment of schizophrenia 
a psychiatry-psychology alliance might be greatly welcomed by frontline care providers 
who are often frustrated and dismayed by the limited effectiveness and all-too-prevalent 
side-effects of medication treatments (Breggin, 1991; Jackson, 2005; Whitaker, 1992). It 
has been the explicit intention of the current theoretical and empirical investigation to 
open a space within which biopsychiatry and psychology can work together, each 
providing the unique tools and insights of their distinct professions.  
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Mirroring the main premise of this dissertation project, Bola (2006) implored researchers 
to consider that psychotherapy outcome research – with and without adjunctive 
medications – should not be prohibited based on the assumptions deconstructed 
throughout this dissertation project. He writes,  
In the absence of substantive evidence of long-term harm from short periods of 
medication-free research in schizophrenia, a categorical prohibition of 
medication-free research in early episode schizophrenia on the ethical grounds of 
harm to human subjects should probably be reconsidered (p. 294).  
Methodological designs for this type of inclusive, non-biased research have been 
provided by Emanuel and Miller (2001), Alanen, (1997), Seikkula et al. (2003) and 
Deikman and Whitaker (1979) among others to help clinicians and researchers 
satisfactorily test the effectiveness of drug and non-drug treatments whether independent 
of each other or combined. Indeed, the time is ripe for researchers and clinicians to 
respond positively to the call for fresh approaches and insights into schizophrenic 
suffering minus the suffocating biases that have held the field back for over half a 
century.  
There are a few significant limitations of the present study. First, although the 
sample size was intentionally limited by the original investigators to control for quality of 
psychotherapy provided to patients, its restricted power necessitates a degree of caution 
when interpreting the results. Future studies might consider using external raters to assess 
treatment fidelity and quality rather than relying on restricted n-size. Such covariates 
would not only allow for increased sample size, but would also provide potentially 
interesting clinical information. Second, patients in this sample were generally urban 
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minorities of a low SES. Studies with a more diverse sample might provide useful 
information pertaining to the effects of these demographic variables. Third, future studies 
should include a mixed treatment group to investigate the effectiveness of combined 
treatments. Due to lost data, the mixed group originally included in Karon and 
Vandenbos (1981) could not be assessed for object relations change. Fourth, the 
Medication patients in this study received older, typical neuroleptics. At first glance, this 
might be deemed a fatal flaw of this study. However, as the CATIE study and other 
recent investigations reported above clearly suggest, the differences between the older 
and newer neurolpetics have been greatly overstated. This is true of clinical improvement 
as well as of troubling side-effects. Most importantly, many of these limitations will only 
be amenable to change if studies such as this one are received with openness and a level 
of scientific inquiry greatly needed if the schizophrenia research and clinical community 
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Table 1. Most Commonly Prescribed Neuroleptic Medications for the Treatment of Schizophrenia 
 
 Generic Name Brand Name 
   
Typical Neuroleptics chlorpromazine Thorazine 
 fluphenazine Prolixin 
 haloperidol Haldol 
 thiothixene Navane 
 trifluoperazine Stelazine 
 perphenazine Trilafon 
 thioridazine Mellaril 
   
Atypical Neuroleptics aripiprazole Abilify 
 risperidone Risperdal 
 clozapine Clozaril 
 olanzapine Seroquel 
 ziprasidone Geodon 




































Low Dose 5mg +/- 2.5 mg 10-20 mg       
Medium Dose 10 mg +/- 2.5 mg 10-20 mg       
High Dose 15 mg +/- 2.5 mg 10-20 mg       




































Table 3. Interrater Reliability of the SCORS Variables 
 










Note. n = 20. aICC = intraclass correlation coefficients (1,1); (Shrout & Fleiss, 1979) one-
way random effects model; bCOM = Complexity of Representations; cAFF = Affect Tone 
of Representations; dEIR = Emotional Investment in Relationships; eEIM = Emotional 
Investment in Values and Morality; fUSC = Understanding of Social Causality; gAGG = 
Experience and Management of Aggressive Impulses; hSE = Self-Esteem; iICS = Identity 

























Table 4. SCORS Means of Outpatients Experiencing Mild to Moderate Distress as Reported in 
Peters et al. (2006) 
Note. n = 90. aCOM = Complexity of Representations; bAFF = Affect Tone of 
Representations; cEIR = Emotional Investment in Relationships; dUSC = Understanding 




SCORS Variable Mean SD
COMa 4.02  .96 
AFFb 3.29 1.02 
EIRc 3.56 .94 
USCd 3.94 .98 
SEe 3.12 .81 
ICSf 3.74 .94 





























Table 5. Convergent and Divergent Validity of the SCORS with a Schizophrenic Sample 
 COMf 
rl          p 
AFFg
r          p 
EIRh
r        p 
USCi
r          p 
SEj 
r         p 
ICSk
r        p 
Hospitala  -.57   .009 -.38 .10 -.39 .09 -.66   .002 -.40 .08 -.68 .001
Verbal IQb  .52   .03 -.04 .90  .08 .76  .45   .01  .16 .54  .37 .15 
Agec  .15   .53 -.15 .51 -.07 .78  .02   .92 -.04 .86  .11 .62 
Educationd  .39   .15 -.01 .97 -.08 .79  .41   .13  .12 .66  .35 .20 
CSIe  .79 <.0001  .50 .02   .42 .06  .71 <.0001  .48 .03  .59 .005
      
Note. aHospital = Total days in hospital through 20-months (n = 21); bVerbal IQ as 
measured by WAIS (Weschler, 1955; n = 17); cAge (n = 21); dEducation (n = 15); eCSI = 
Clinical Status Interview assessing global health-sickness and psychiatric 
symptomatology (n = 21); fCOM = Complexity of Representations; gAFF = Affect Tone 
of Representations; hEIR = Emotional Investment in Relationships; iUSC = 
Understanding of Social Causality; jSE = Self-Esteem; kICS = Identity and Coherence of 
the Self; lPearson r correlational coefficients are considered to represent a small effect 





























Table 6. Means, Standard Deviations, and Paired-Samples T Tests for Psychotherapy Group 
 
 Psychotherapy (n = 9)     
 Pre-Treatment 
  M                SD 
Post-Treatment 









COMa 1.64              .36 3.20             1.06 8 4.46 .002 3.15 
AFFb 2.82              .54 3.59               .63 8 3.89 .005 2.75 
EIRc 2.21              .36 2.79               .78 8 2.39 .04 2.39 
USCd 1.69              .36 3.16               .92 8 6.53 .0001 4.62 
SE e 2.76              .47 3.72               .53 8 4.53 .002 3.20 
ICSf 2.86              .57 4.11               .55 8 5.01 .001 3.54 
    
Note. aCOM = Complexity of Representations; bAFF = Affect Tone of Representations; 
cEIR = Emotional Investment in Relationships; dUSC = Understanding of Social 
Causality; eSE = Self-Esteem; fICS = Identity and Coherence of the Self; g ES = effect 
size Cohen’s (1977) d; hCohen’s d effect sizes are considered to represent a small effect 





























Table 7. Means, Standard Deviations, and Paired-Samples T Tests for Medication Group 
 Medication (n = 12)     
 Pre-Treatment 
  M                SD 
Post-Treatment 









COMa 2.02              .64 2.65              .79 11 2.67 .02 1.61 
AFFb 2.85              .72 3.08              .73 11 1.25 .24 0.75 
EIRc 1.98              .57 2.52              .68 11 3.29 .007 1.98 
USCd 2.00              .68 2.53              .85 11 2.04 .07 1.23 
SE e 3.07              .64 
Note. aCOM = Complexity of Representations; bAFF = Affect Tone of Representations; 
cEIR = Emotional Investment in Relationships; dUSC = Understanding of Social 
Causality; eSE = Self-Esteem; fICS = Identity and Coherence of the Self; g ES = effect 
size Cohen’s (1977) d; hCohen’s d effect sizes are considered to represent a small effect 
from .2 to .5, a medium effect from .5 to .8, and a large effect if greater than .8.  
3.27              .55 11 0.91 .38 0.55 
ICSf 3.03              .98 3.58              .70 11 1.74 .11 1.05 






























Table 8. Traditional Analyses of Between-Groups Change Using ‘Difference Scores’ 
 Psychotherapy (n = 9) 
 
M         SD 
Medication (n = 12) 
 













COMa 1.56         1.05 0.63        0.82 19 2.27 .04 1.05 
AFFb 0.77        0.59 0.23       0.65 19 1.94 .07 0.90 
EIRc 0.58        0.73 0.53        0.56 19 0.18 .86 0.08 
USCd 1.47        0.68       0.53        0.90 19 2.61 .02 1.21 
SEe 0.97        .64 0.20        0.77 19 2.40 .03 1.13 
ICSf 1.25        0.75 0.55        1.09 
Note. aCOM = Complexity of Representations; bAFF = Affect Tone of Representations; 
cEIR = Emotional Investment in Relationships; dUSC = Understanding of Social 
Causality; eSE = Self-Esteem; fICS = Identity and Coherence of the Self; g ES = effect 
size Cohen’s (1977) d; hCohen’s d effect sizes are considered to represent a small effect 
from .2 to .5, a medium effect from .5 to .8, and a large effect if greater than .8.  
19 1.65 .12 0.77 






















Table 9. Number of Individual Psychotherapy and Medication Patients Meeting Clinical Significance 
Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS Complexity of 
Representations (COM) 
Medication (n = 12)  
Criterion 
Psychotherapy (n = 9) 
Improved         Deteriorated Improved              Deteriorated 
RCI > 1.96 









































     
RCI > 1.28 














     
RCI > 1.96 and 
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Table 10. Number of Individual Psychotherapy and Medication Patients Meeting Clinical 
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS Affect 
Tone of Representations (AFF) 
 
Criterion 
Psychotherapy (n = 9) 
Improved         Deteriorated 
Medication (n = 12) 
Improved              Deteriorated 
RCI > 1.96 














     
RCI > 1.28 













     
RCI > 1.96 and 
Peters et al. (2006) 
 
3 (33%) 
   
n/a 0 (0%) n/a 
   





























Table 11. Number of Individual Psychotherapy and Medication Patients Meeting Clinical 
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS 
Emotional Investment in Relationships (EIR) 
Medication (n = 12)  
Criterion 
Psychotherapy (n = 9) 
Improved         Deteriorated Improved              Deteriorated 
RCI > 1.96 














     
RCI > 1.28 







































     
RCI > 1.96 and 
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Table 12. Number of Individual Psychotherapy and Medication Patients Meeting Clinical 
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS 
Understanding of Social Causality (USC) 
 
Criterion 
Psychotherapy (n = 9) 
Improved         Deteriorated 
Medication (n = 12) 
Improved              Deteriorated 
RCI > 1.96 














     
RCI > 1.28 









































     
RCI > 1.96 and 
Peters et al. (2006) 
    
2 (22%) n/a 0 (0%) n/a 
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Table 13. Number of Individual Psychotherapy and Medication Patients Meeting Clinical 
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS Self-
Esteem (SE) 
Medication (n = 12)Psychotherapy (n = 9)






























Improved         Deteriorated 
 
Improved              Deteriorated 
RCI > 1.96 6 0 2 1 
SD > 2.0 2 0 0 0 
‘Recovered’a 2 (22%) 0 (0%) 0 (0%) 0 (0%) 
     
RCI > 1.28 7 0 4  1 
SD > 1.0 4 0 5 1 
‘Positive’b 4 (44%) 0 (0%) 3 (25%) 1 (8%) 
     
RCI > 1.96 and     
Peters et al. (2006) 5 (56%) n/a 0 (0%) n/a 
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Table 14. Number of Individual Psychotherapy and Medication Patients Meeting Clinical 
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS 
Identity and Coherence of the Self  (ICS) 
Medication (n = 12)Psychotherapy (n = 9)






























Improved         Deteriorated 
 
Improved              Deteriorated 
RCI > 1.96 6 0 3 1 
SD > 2.0 1 0 0 0 
‘Recovered’a 1 (11%) 0 (0%) 0 (0%) 0 (0%) 
     
RCI > 1.28 7 0 6 1 
SD > 1.0 6 0 6 1 
‘Positive’b 6 (67%) 0 (0%) 4 (33%)  1 (8%) 
     
RCI > 1.96 and     
Peters et al. (2006) 6 (67%) n/a 3 (25%) n/a 
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Table 15. Number of Individual Psychotherapy and Medication Patients Meeting Clinical 
Significance Criteria for ‘Recovered’ and ‘Positive Response’ for SCORS-C 
Psychotherapy (n = 9) Medication (n = 12) 

































Improved         Deteriorated 
 
Improved              Deteriorated 
RCI > 1.96 6 0 4 0 
SD > 2.0 4 0 3 0 
‘Recovered’a 4 (44%) 0 (0%) 1 (8%) 0 (0%) 
     
RCI > 1.28 7 0 5 1 
SD > 1.0 7 0 5 1 
‘Positive’b 7 (78%) 0 (0%) 4 (33%) 1 (8%) 
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Table 16. Differences in RCI between Psychotherapy and Medication Treatments 
Note. aCOM = Complexity of Representations; bAFF = Affect Tone of Representations; 
cEIR = Emotional Investment in Relationships; dUSC = Understanding of Social 
Causality; eSE = Self-Esteem; fICS = Identity and Coherence of the Self; g ES = effect 
size Cohen’s (1977) d; hCohen’s d effect sizes are considered to represent a small effect 




















 Psychotherapy (n = 9) Medication (n = 12) 
 
M         SD 
     
     
ES dgh M         SD df t p 
COMa 3.50         2.44 1.59        1.78 19 2.08 .05 0.92 
AFFb 1.59        1.14 0.55        1.20 19 2.01 .06 0.89 
EIRc 1.78        2.10 1.47        1.56 19 0.38 .71 0.18 
USCd 3.47        1.79 1.38        2.05 19 2.44 .03 1.08 
SEe 2.30        1.45 0.59        1.68 19 2.45 .02 1.08 
ICSf 2.21        1.20 1.02        1.67 19 1.81 .09 0.80 
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